{"altmetric_id":10065061,"counts":{"readers":{"mendeley":103,"citeulike":0,"connotea":0},"total":{"posts_count":230},"news":{"unique_users_count":59,"unique_users":["wboc_16","wtoc","stock_nod_quotes","hawaii_news_now","ticker_tech","wsfa","kltv","wistv","newson6","kusi_news","news_9","fox_14_news","wtvm","minyanville_finance","wrcb_tv","14_news","news_channel","ktre","khq","kx_news","wlox","mississippi_news_now","south_carolina_news_now","wave_3_news","tucson_news_now","yahoo_news","wmbf_news","48_waff","wtol","kfve_the_home_team","fox_wilmington","wand_17","wdrb","kten","cleveland_19","klkn_tv_eyewitness_news","2_news","abc_40","wmc_action_news_5","cw_richmond","abc_6_news_wlne","abc_7_news_kswo","news_channel_6","kuam","wltz","nbc12","pr_newswire","kplc_7_news","bioportfolio","walb","ksla_news_12","newswest9","wfmj","nbc_right_now_kndu_25","kait_tv","wdam_tv","wflx_fox_29","cbs8","kcbd"],"posts_count":111},"twitter":{"unique_users_count":81,"unique_users":["elfarodehuse","VincentRK","IMFmyeloma","bhemato","fifyfo","Cytognos","glorinharegina","MayoMyeloma","ChrisBoatner","hemaoncol","nbferrara","pharmaNGS","mtmdphd","ClinOncNews","DrAnasYounes","MayoClinic","Utopain","DrSarahBHealthy","TheScientifiK","mustafaalid","MRISoundImaging","MyGood_Health1","NicoleRdcs","pvlummen","hazim20014","FarmaOnco","dzivalj","paulajgt","TheLancetOncol","CancerWallonia","TheBindingSite","BindingSiteHaem","gwenniejacques","TiengJackie","beatl51","jose6xxx","ONKOSconsulting","szusmani","Transplant_Doc","marinellopatri","M_E_Atiya","psharmaMD","alantanmd","VJHemOnc","akeithstewart","Aurora_Cancer","dianis_nm","MyelomaTeacher","ACCCBuzz","neuherman","Taxkourel","Dr_Chen_Wang","Mohty_EBMT","VaroqueauxN","CGiampalmi","NextGEN_Ltd","MayoCancerCare","AnaRRubio","MistyACallahan","PublicHealthRTs","ThiloZander","afshanmalikmd","SandyWong02111","Cecilia_Hemato","Celgene_Myeloma","myeloma_samps","lascocancerfund","pmctrawler","agarwalonc","IMFsupport","leshune","dr_abdulaleem","queizan","elyarams","DQBMD","AdaptiveBiotech","Sorena997","razan_mohty","sarah_0875","elizabeth_dorcy","rodrigonunescal"],"posts_count":116},"peer_reviews":{"unique_users_count":1,"unique_users":["pubpeer"],"posts_count":1},"facebook":{"unique_users_count":2,"unique_users":["909065465843062","1673989042868936"],"posts_count":2}},"selected_quotes":["IMWG consensus criteria for response MRD assessment in myeloma","Breaking news: new response criteria for #myeloma ; includes #MRD definition.","International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in MM","New response criteria for #myeloma","International Myeloma Working Group defines new response categories for multiple #myeloma"],"citation":{"abstract":"Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of response. Response criteria in multiple myeloma were developed to use serum and urine assessment of monoclonal proteins and bone marrow assessment (which is relatively insensitive). Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, new response categories need to be defined that can identify responses that are deeper than those conventionally defined as complete response. Recent attempts have focused on the identification of residual tumour cells in the bone marrow using flow cytometry or gene sequencing. Furthermore, sensitive imaging techniques can be used to detect the presence of residual disease outside of the bone marrow. Combining these new methods, the International Myeloma Working Group has defined new response categories of minimal residual disease negativity, with or without imaging-based absence of extramedullary disease, to allow uniform reporting within and outside clinical trials. In this Review, we clarify several aspects of disease response assessment, along with endpoints for clinical trials, and highlight future directions for disease response assessments.","altmetric_jid":"4f6fa4f73cf058f610002fd1","authors":["Shaji Kumar","Bruno Paiva","Kenneth C Anderson","Brian Durie","Ola Landgren","Philippe Moreau","Nikhil Munshi","Sagar Lonial","Joan Blad\u00e9","Maria-Victoria Mateos","Meletios Dimopoulos","Efstathios Kastritis","Mario Boccadoro","Robert Orlowski","Hartmut Goldschmidt","Andrew Spencer","Jian Hou","Wee Joo Chng","Saad Z Usmani","Elena Zamagni","Kazuyuki Shimizu","Sundar Jagannath","Hans E Johnsen","Evangelos Terpos","Anthony Reiman","Robert A Kyle","Pieter Sonneveld","Paul G Richardson","Philip McCarthy","Heinz Ludwig","Wenming Chen","Michele Cavo","Jean-Luc Harousseau","Suzanne Lentzsch","Jens Hillengass","Antonio Palumbo","Alberto Orfao","S Vincent Rajkumar","Jesus San Miguel","Herve Avet-Loiseau","Kumar, Shaji","Paiva, Bruno","Anderson, Kenneth C","Durie, Brian","Landgren, Ola","Moreau, Philippe","Munshi, Nikhil","Lonial, Sagar","Blad\u00e9, Joan","Mateos, Maria-Victoria","Dimopoulos, Meletios","Kastritis, Efstathios","Boccadoro, Mario","Orlowski, Robert","Goldschmidt, Hartmut","Spencer, Andrew","Hou, Jian","Chng, Wee Joo","Usmani, Saad Z","Zamagni, Elena","Shimizu, Kazuyuki","Jagannath, Sundar","Johnsen, Hans E","Terpos, Evangelos","Reiman, Anthony","Kyle, Robert A","Sonneveld, Pieter","Richardson, Paul G","McCarthy, Philip","Ludwig, Heinz","Chen, Wenming","Cavo, Michele","Harousseau, Jean-Luc","Lentzsch, Suzanne","Hillengass, Jens","Palumbo, Antonio","Orfao, Alberto","Rajkumar, S Vincent","San Miguel, Jesus","Avet-Loiseau, Herve"],"doi":"10.1016\/s1470-2045(16)30206-6","endpage":"e346","first_seen_on":"2016-07-27T09:59:18+00:00","funders":["niehs"],"issns":["14702045","1474-5488"],"issue":"8","journal":"Lancet Oncology","last_mentioned_on":1493674960,"links":["https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/fulltext?elsca1%3Detoc&rc=0&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/fulltext&rc=0&code=lancet-site","http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1470204516302066","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/fulltext?linkId%3D26996638&rc=0&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/fulltext?rss%3Dyes&rc=0&code=lancet-site","http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/abstract","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/fulltext?platform%3Dhootsuite&rc=0&code=lancet-site","http:\/\/dx.doi.org\/10.1016\/S1470-2045(16)30206-6","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/fulltext&rc=0&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/www.thelancet.com\/pdfs\/journals\/lanonc\/PIIS1470-2045(16)30206-6.pdf&rc=0&code=lancet-site","http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/fulltext?rss=yes#.V5t55czEH5o.twitter","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27511158","http:\/\/www.ncbi.nlm.nih.gov\/m\/pubmed\/27511158\/?i=6&from=myeloma","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/fulltext?linkId%3D27573646&rc=0&code=lancet-site","http:\/\/thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/fulltext","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27511158","http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/fulltext?rss=yes","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=8&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045%2816%2930206-6%2Fabstract&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=8&redirect=http%3A%2F%2Fthelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045%2816%2930206-6%2Ffulltext&code=lancet-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=9&redirect=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045%2816%2930206-6%2Ffulltext&code=lancet-site","http:\/\/thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30206-6\/references","http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045%2816%2930206-6\/abstract#.WCEoiRLqWYk.twitter"],"pdf_url":"http:\/\/thelancet.com\/article\/S1470204516302066\/pdf","pmid":"27511158","pubdate":"2016-08-01T00:00:00+00:00","publisher":"Elsevier","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"e328","subjects":["neoplasms"],"title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","type":"article","uri":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204516302066","volume":"17","mendeley_url":"http:\/\/www.mendeley.com\/research\/international-myeloma-working-group-consensus-criteria-response-minimal-residual-disease-assessment-2"},"altmetric_score":{"score":521.75,"score_history":{"1y":433.2,"6m":1.25,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":521.75},"context_for_score":{"all":{"total_number_of_other_articles":8376947,"mean":7.0581144861071,"rank":7559,"this_scored_higher_than_pct":99,"this_scored_higher_than":8369403,"rank_type":"exact","sample_size":8376947,"percentile":99},"similar_age_3m":{"total_number_of_other_articles":260350,"mean":12.004513841036,"rank":700,"this_scored_higher_than_pct":99,"this_scored_higher_than":259650,"rank_type":"exact","sample_size":260350,"percentile":99},"this_journal":{"total_number_of_other_articles":3590,"mean":18.228461967122,"rank":14,"this_scored_higher_than_pct":99,"this_scored_higher_than":3576,"rank_type":"exact","sample_size":3590,"percentile":99},"similar_age_this_journal_3m":{"total_number_of_other_articles":148,"mean":33.767387755102,"rank":3,"this_scored_higher_than_pct":97,"this_scored_higher_than":145,"rank_type":"exact","sample_size":148,"percentile":97}}},"demographics":{"poster_types":{"member_of_the_public":58,"researcher":11,"practitioner":9,"science_communicator":3},"users":{"twitter":{"cohorts":{"Practitioners (doctors, other healthcare professionals)":9,"Scientists":11,"Members of the public":58,"Science communicators (journalists, bloggers, editors)":3}},"mendeley":{"by_status":{"Unspecified":2,"Professor > Associate Professor":5,"Librarian":3,"Researcher":19,"Student  > Doctoral Student":8,"Student  > Ph. D. Student":15,"Student  > Postgraduate":6,"Student  > Master":12,"Other":16,"Student  > Bachelor":8,"Lecturer":1,"Lecturer > Senior Lecturer":2,"Professor":6},"by_discipline":{"Medicine and Dentistry":65,"Psychology":1,"Mathematics":1,"Unspecified":4,"Pharmacology, Toxicology and Pharmaceutical Science":4,"Arts and Humanities":3,"Engineering":1,"Economics, Econometrics and Finance":1,"Immunology and Microbiology":7,"Agricultural and Biological Sciences":9,"Computer Science":1,"Biochemistry, Genetics and Molecular Biology":5,"Philosophy":1}}},"geo":{"twitter":{"ES":3,"US":28,"KR":1,"GB":4,"BE":1,"HR":1,"TW":1,"MX":1,"DK":1,"CH":1,"NO":1,"CA":1,"IN":1,"BR":1},"mendeley":{"CZ":1,"US":1,"JP":1,"DK":2}}},"posts":{"news":[{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478747251&p=1pl&v=1&x=HQTuEiKP17hdCK_AxpV-pw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:19:36+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WBOC 16","url":"http:\/\/www.wboc.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/717\/normal\/Screen_Shot_2016-01-26_at_15.23.21.png?1453821908"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478871388&p=1pl&v=1&x=nkZaDnrDQ1Mg0OfIGfQyNA","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:32:43+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WTOC","url":"http:\/\/www.wtoc.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/688\/normal\/Screen_Shot_2016-01-26_at_14.30.16.png?1453818642"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409856969&p=1pl&v=1&x=txhd0bXDCGIrX-E-4z_Qaw","license":"public","citation_ids":[10065061,10065061],"posted_on":"2016-07-27T13:00:00+00:00","summary":"NORTH HOLLYWOOD, Calif. The consensus authored by the International Myeloma Working Group (IMWG), a research division of the IMF, and published today in The Lancet Oncology \"The treatment landscape for multiple myeloma has been radically transformed\u2026","author":{"name":"Stock Nod: Quotes","url":"http:\/\/quotes.stocknod.com\/stocknod","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/671\/normal\/Screen_Shot_2016-01-26_at_13.59.47.png?1453816868"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409860928&p=1pl&v=1&x=WsOfvaZOoFaN04nFbj3ZtA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:04:01+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"Hawaii News Now","url":"http:\/\/www.hawaiinewsnow.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/661\/normal\/Screen_Shot_2016-01-26_at_12.16.42.png?1453810633"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409866759&p=1pl&v=1&x=3P1X-r7PM2pAHPfQgZluaw","license":"public","citation_ids":[10065061,10065061],"posted_on":"2016-07-27T13:04:31+00:00","summary":"\/PRNewswire-USNewswire\/ -- The International Myeloma Foundation (IMF) \u2013 the oldest and largest organization dedicated to improving the lives of myeloma patients while working toward prevention and a cure \u2013 says researchers have now established the\u2026","author":{"name":"Ticker Tech","url":"http:\/\/www.tickertech.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/724\/normal\/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409869069&p=1pl&v=1&x=_5EEVv9knftp-3y9qupUGA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:04:41+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WSFA ","url":"http:\/\/www.wsfa.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/644\/normal\/Screen_Shot_2016-01-26_at_11.40.39.png?1453808470"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409871308&p=1pl&v=1&x=CPBHLCEjcTv-1MSq83dxGg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:04:51+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WTOC","url":"http:\/\/www.wtoc.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/688\/normal\/Screen_Shot_2016-01-26_at_14.30.16.png?1453818642"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409872139&p=1pl&v=1&x=jY2rfjESkRHSSNOX_qo3Hg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:04:55+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KLTV","url":"http:\/\/www.kltv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/704\/normal\/Screen_Shot_2016-01-26_at_14.54.15.png?1453820113"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409873693&p=1pl&v=1&x=qcdi9NVzFR95JvJu14TV0w","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:05:02+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WISTV","url":"http:\/\/www.wistv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/689\/normal\/Screen_Shot_2016-01-26_at_14.30.56.png?1453818748"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409875637&p=1pl&v=1&x=XD4a71Y3B4Ty6JRotgktWg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:05:12+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"NewsOn6","url":"http:\/\/www.newson6.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/677\/normal\/Screen_Shot_2016-01-26_at_14.12.15.png?1453817572"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409877273&p=1pl&v=1&x=f1m3GZJ3vfhG8Gv50uBEPg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:05:20+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KUSI News","url":"http:\/\/www.kusi.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/663\/normal\/Screen_Shot_2016-01-26_at_13.26.05.png?1453815145"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409878250&p=1pl&v=1&x=pZCBWathQtLf2180jaIkMw","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"News 9","url":"http:\/\/www.news9.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/691\/normal\/Screen_Shot_2016-01-26_at_14.34.55.png?1453818924"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409881011&p=1pl&v=1&x=9gNftalxVTUmbhi38d0XGg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:05:38+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"Fox 14 News","url":"http:\/\/www.fox14tv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/651\/normal\/Screen_Shot_2016-01-26_at_12.00.07.png?1453809650"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409884312&p=1pl&v=1&x=KTy1VO7_rfnhWkWN1WsiLQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:05:57+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WTVM","url":"http:\/\/www.wtvm.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/646\/normal\/Screen_Shot_2016-02-02_at_14.58.13.png?1454425111"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409890589&p=1pl&v=1&x=-4EzwbxLSivHYXma6HyxLg","license":"public","citation_ids":[10065061,10065061],"posted_on":"2016-07-27T13:00:00+00:00","summary":"NORTH HOLLYWOOD, Calif., July 27, 2016 \/PRNewswire-USNewswire\/ -- The International Myeloma Foundation (IMF) \u2013 the oldest and largest organization dedicated to improving the lives of myeloma patients while working toward prevention and a cure \u2026","author":{"name":"Minyanville: Finance ","url":"http:\/\/finance.minyanville.com\/minyanville","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/637\/normal\/Screen_Shot_2016-02-02_at_16.44.51.png?1454431502"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409893833&p=1pl&v=1&x=VoCF_JQIeGvwehtEc-xu5w","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WRCB- TV","url":"http:\/\/www.wrcbtv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/690\/normal\/Screen_Shot_2016-01-26_at_14.32.42.png?1453818828"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409902747&p=1pl&v=1&x=kuPulGycpkhrO4bSGC1CIQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:07:28+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"14 News","url":"http:\/\/www.14news.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/696\/normal\/Screen_Shot_2016-01-26_at_14.43.50.png?1453819462"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409904268&p=1pl&v=1&x=6IlQjt2J_yG0bDGIrQVKrA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"News Channel","url":"http:\/\/www.kxxv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/645\/normal\/Screen_Shot_2016-01-26_at_11.42.27.png?1453808595"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409907328&p=1pl&v=1&x=lAkGYulI4H_idNHRnZGT_A","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KTRE","url":"http:\/\/www.ktre.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/705\/normal\/Screen_Shot_2016-01-26_at_15.04.21.png?1453820750"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409911638&p=1pl&v=1&x=Z2T2oZ8bUZ7pny5dEudG4Q","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:08:16+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KHQ","url":"http:\/\/www.khq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/658\/normal\/Screen_Shot_2016-01-26_at_12.10.14.png?1453810239"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409912672&p=1pl&v=1&x=jdyGldIuqSXG3WM5G-pPZA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:08:21+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KX News","url":"http:\/\/www.kxnet.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/650\/normal\/Screen_Shot_2016-01-26_at_11.58.45.png?1453809587"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409913700&p=1pl&v=1&x=OiiTGMZBPmiiEn7Tos8EZQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WLOX","url":"http:\/\/www.wlox.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/657\/normal\/Screen_Shot_2016-01-26_at_12.08.48.png?1453810156"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409917285&p=1pl&v=1&x=RoEtewMVj_OHOdV4HDWDFA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:08:47+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"Mississippi News Now ","url":"http:\/\/www.msnewsnow.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/649\/normal\/Screen_Shot_2016-01-26_at_11.57.00.png?1453809440"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409917556&p=1pl&v=1&x=EmyUqE3Ct10olDzhhAQfwg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:08:50+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"South Carolina News Now","url":"http:\/\/www.live5news.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/730\/normal\/Screen_Shot_2016-01-26_at_15.47.02.png?1453823263"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409921416&p=1pl&v=1&x=fJsE0xYFe_Ac0biaTxdvYQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"Wave 3 News","url":"http:\/\/www.wave3.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/697\/normal\/Screen_Shot_2016-01-26_at_14.44.55.png?1453819521"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409923209&p=1pl&v=1&x=CFTIeSBfsu9FXvj2Dg4zBw","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:09:23+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"Tucson News Now","url":"http:\/\/www.tucsonnewsnow.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/812\/normal\/Screen_Shot_2016-01-27_at_10.13.49.png?1453889665"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409925193&p=1pl&v=1&x=N03mR2Pqq7yeqdlvS68UQA","license":"public","citation_ids":[10065061,10065061],"posted_on":"2016-07-27T13:00:00+00:00","summary":"NORTH HOLLYWOOD, Calif., July 27, 2016 \/PRNewswire-USNewswire\/ -- The International Myeloma Foundation (IMF) \u2013 the oldest and largest organization dedicated to improving the lives of myeloma patients while working toward prevention and a cure \u2013 says\u2026","author":{"name":"Yahoo! News","url":"http:\/\/news.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/032\/normal\/yahoo_news.png?1369846922"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409927496&p=1pl&v=1&x=W7vBVwQQvLEtjfefuUMdYg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:09:47+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WMBF News","url":"http:\/\/www.wmbfnews.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/710\/normal\/Screen_Shot_2016-01-26_at_15.11.39.png?1453821128"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409927682&p=1pl&v=1&x=yiErRk2bTDpdFh1gCZtASg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"48 WAFF","url":"http:\/\/www.waff.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/699\/normal\/Screen_Shot_2016-01-26_at_14.47.41.png?1453819680"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409927890&p=1pl&v=1&x=s_VhUXMCpiTuw73dUzBfNA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:09:50+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WTOL","url":"http:\/\/www.wtol.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/662\/normal\/Screen_Shot_2016-01-26_at_12.19.14.png?1453810785"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409933520&p=1pl&v=1&x=wcyM5KQYiQI3uOVaak-UYg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KFVE The Home Team","url":"http:\/\/www.k5thehometeam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/734\/normal\/Screen_Shot_2016-01-26_at_15.53.15.png?1453823633"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409933699&p=1pl&v=1&x=1XbanZH350a8Gbmeys4ZUQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:10:25+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"Fox Wilmington","url":"http:\/\/www.wsfx.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/740\/normal\/Screen_Shot_2016-01-26_at_16.09.52.png?1453824618"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409934334&p=1pl&v=1&x=7JOCkXtO_95-pRQDPxu9yQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:04:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WAND 17","url":"http:\/\/www.wandtv.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/694\/normal\/Screen_Shot_2016-01-26_at_14.41.02.png?1453819294"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409943240&p=1pl&v=1&x=BEzF-BlhR7g76ZWJOnAT3g","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:11:15+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WDRB","url":"http:\/\/www.wdrb.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/693\/normal\/Screen_Shot_2016-01-26_at_14.37.05.png?1453819066"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409962624&p=1pl&v=1&x=dCtoxqAEMDm445lTFFbVWA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:04:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KTEN","url":"http:\/\/www.kten.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/643\/normal\/Screen_Shot_2016-01-26_at_11.36.58.png?1453808251"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409965386&p=1pl&v=1&x=18DvIVXzaiHK8noFc63I_w","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:13:15+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"Cleveland 19","url":"http:\/\/www.cleveland19.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/683\/normal\/Screen_Shot_2016-01-26_at_14.20.50.png?1453818081"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409965453&p=1pl&v=1&x=nNmTonhSS4DLnQyovS7V_A","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:04:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KLKN-TV Eyewitness News","url":"http:\/\/www.klkntv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/655\/normal\/Screen_Shot_2016-01-26_at_12.06.08.png?1453810028"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409968480&p=1pl&v=1&x=g-ODg3Yx2v1XVU5RRS866w","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"2 News","url":"http:\/\/www.ktvn.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/654\/normal\/Screen_Shot_2016-01-26_at_12.05.19.png?1453809947"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409973086&p=1pl&v=1&x=45j8L_aUlrVwN_ljR1gnHw","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:14:08+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"ABC 40","url":"http:\/\/www.abc40.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/698\/normal\/Screen_Shot_2016-01-26_at_14.45.46.png?1453819612"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409987766&p=1pl&v=1&x=1VBaZkKH6NSekZuuQOcAzw","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:15:32+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WMC Action News 5","url":"http:\/\/www.wmcactionnews5.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/727\/normal\/Screen_Shot_2016-01-26_at_15.42.23.png?1453822987"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409988838&p=1pl&v=1&x=dSrRuoDOBwJlVtVX0rZSjw","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:15:38+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"CW: Richmond","url":"http:\/\/www.cwrichmond.tv","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/648\/normal\/Screen_Shot_2016-01-26_at_11.48.33.png?1453809040"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27409994120&p=1pl&v=1&x=8y2Lf7D-zZ4Sbg4OSbwYyQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"ABC 6 News WLNE","url":"http:\/\/www.abc6.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/712\/normal\/Screen_Shot_2016-01-26_at_15.16.08.png?1453821391"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410000003&p=1pl&v=1&x=uHfNWZAZRGXDA_8DejIIlg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:16:37+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"ABC 7 News KSWO","url":"http:\/\/www.kswo.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/708\/normal\/Screen_Shot_2016-01-26_at_15.08.58.png?1453821021"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410002725&p=1pl&v=1&x=nmv1jOIk1x9ELbugJ8pyLQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"News Channel 6","url":"http:\/\/www.newschannel6now.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/652\/normal\/Screen_Shot_2016-01-26_at_12.01.23.png?1453809711"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410005738&p=1pl&v=1&x=l3YfR69SMPtoRkpSBZv0qA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:17:06+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"Kuam","url":"http:\/\/www.kuam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/667\/normal\/Screen_Shot_2016-01-26_at_13.48.34.png?1453816300"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410018207&p=1pl&v=1&x=qbbyDjGYuAurRdpQolqgcg","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:18:23+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WLTZ","url":"http:\/\/www.wltz.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/653\/normal\/Screen_Shot_2016-01-26_at_12.04.16.png?1453809879"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410021880&p=1pl&v=1&x=B9adOaCw6wd9Ge3CwoKgpQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:18:44+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"NBC12","url":"http:\/\/www.nbc12.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/702\/normal\/Screen_Shot_2016-01-26_at_14.51.21.png?1453819926"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410025131&p=1pl&v=1&x=8H4kB021GHHiM-ZJF93PHw","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:00:00+00:00","summary":"New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif., July 27, 2016 \/PRNewswire-USNewswire\/ -- The International Myeloma Foundation (IMF) \u2013 the oldest and largest\u2026","author":{"name":"PR Newswire","url":"http:\/\/www.prnewswire.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/545\/normal\/Screen_Shot_2016-01-06_at_16.29.18.png?1452097789"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410038493&p=1pl&v=1&x=6OZ3vaBb-ztLAjBnOUw2_g","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KPLC 7 News","url":"http:\/\/www.kplctv.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/641\/normal\/Screen_Shot_2016-01-26_at_11.30.17.png?1453807834"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410041288&p=1pl&v=1&x=Hf-yCkIgeLJtsk-FNTN9gg","license":"public","citation_ids":[10065061,10065061],"posted_on":"2016-07-27T13:20:44+00:00","summary":"NORTH HOLLYWOOD, Calif., July 27, 2016 \/PRNewswire-USNewswire\/ -- The International Myeloma Foundation (IMF) \u2013 the oldest and largest organization dedicated to improving the lives of myeloma patients while working toward prevention and a cure \u2013 says\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410042645&p=1pl&v=1&x=eUJX7Mw59RLetNGw8ynktA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:20:51+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WBOC 16","url":"http:\/\/www.wboc.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/717\/normal\/Screen_Shot_2016-01-26_at_15.23.21.png?1453821908"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410048603&p=1pl&v=1&x=76rx1_nQyJftMAQeCTdzkw","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WALB","url":"http:\/\/www.walb.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/647\/normal\/Screen_Shot_2016-01-26_at_11.47.02.png?1453808851"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410054281&p=1pl&v=1&x=mDckvqN46cq7Bdfx_3g6dA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:22:06+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KSLA News 12","url":"http:\/\/www.ksla.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/709\/normal\/Screen_Shot_2016-01-26_at_15.10.50.png?1453821079"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410057727&p=1pl&v=1&x=hiz4Hu_z2yxBuoC1gF4MeQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:22:27+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"NewsWest9","url":"http:\/\/www.newswest9.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/703\/normal\/Screen_Shot_2016-01-26_at_14.52.45.png?1453820009"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410061368&p=1pl&v=1&x=99VYk7UDhwS6k-osjzngHQ","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WFMJ","url":"http:\/\/www.wfmj.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/701\/normal\/Screen_Shot_2016-01-26_at_14.49.34.png?1453819812"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410062783&p=1pl&v=1&x=SRqWGMhQJ0fc69zr6ZdPAA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:22:58+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"NBC Right Now KNDU 25","url":"http:\/\/www.nbcrightnow.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/735\/normal\/Screen_Shot_2016-01-26_at_15.54.16.png?1453823699"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410072356&p=1pl&v=1&x=2UZ7X4Mrw4MoTYOqXZmqGA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:23:48+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"KAIT-TV","url":"http:\/\/www.kait8.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/672\/normal\/Screen_Shot_2016-01-26_at_14.02.53.png?1453817085"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410078983&p=1pl&v=1&x=_b7GbAwDD0CE2ZF-eOE51Q","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:24:28+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WDAM - TV","url":"http:\/\/www.wdam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/682\/normal\/Screen_Shot_2016-01-26_at_14.19.46.png?1453818016"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410094900&p=1pl&v=1&x=NJB3W7mP3VTXCVah63EqQA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:03:00+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"WFLX Fox 29","url":"http:\/\/www.wflx.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/656\/normal\/Screen_Shot_2016-01-26_at_12.07.36.png?1453810094"}},{"title":"The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016","url":"http:\/\/ct.moreover.com\/?a=27410134421&p=1pl&v=1&x=8VD04UQ4lii4zFYx0lL1kA","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T13:30:06+00:00","summary":"SOURCE International Myeloma Foundation New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure NORTH HOLLYWOOD, Calif.","author":{"name":"CBS8","url":"http:\/\/www.cbs8.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/681\/normal\/Screen_Shot_2016-01-26_at_14.17.19.png?1453817863"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478079654&p=1pl&v=1&x=XRpnXqeUazGAvbHwZNm2Sg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:08:14+00:00","summary":"LOS ANGELES, Nov. 2, 2016 \/PRNewswire-USNewswire\/ -- The International Myeloma Foundation (IMF) \u2013 improving the quality of life of myeloma patients while working toward prevention and a cure \u2013 is pleased to announce that the National Comprehensive\u2026","author":{"name":"Ticker Tech","url":"http:\/\/www.tickertech.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/724\/normal\/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478082521&p=1pl&v=1&x=o-5MCgbgxt9FWI1sQ_IMow","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:00:00+00:00","summary":"LOS ANGELES, Nov. 2, 2016 \/PRNewswire-USNewswire\/ -- The International Myeloma Foundation (IMF) \u2013 improving the quality of life of myeloma patients while working toward prevention and a cure \u2013 is pleased to announce that the National Comprehensive\u2026","author":{"name":"Yahoo! News","url":"http:\/\/news.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/032\/normal\/yahoo_news.png?1369846922"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478235700&p=1pl&v=1&x=kZdw9-0W-W52hJ3nu1N8Aw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:00:00+00:00","summary":"Action Underscores Value of MRD Assessment in Multiple Myeloma News provided by Share this article LOS ANGELES, Nov.","author":{"name":"PR Newswire","url":"http:\/\/www.prnewswire.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/545\/normal\/Screen_Shot_2016-01-06_at_16.29.18.png?1452097789"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478473494&p=1pl&v=1&x=YyMU_YWYFKb-JcZFjTJSjg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:50:00+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KFVE The Home Team","url":"http:\/\/www.k5thehometeam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/734\/normal\/Screen_Shot_2016-01-26_at_15.53.15.png?1453823633"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478486022&p=1pl&v=1&x=R1GzEtxtfweGcXY1l4Ccvg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:50:00+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KPLC 7 News","url":"http:\/\/www.kplctv.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/641\/normal\/Screen_Shot_2016-01-26_at_11.30.17.png?1453807834"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478488620&p=1pl&v=1&x=gvbQDtcZMgnYI524nY44Ww","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:52:20+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"Tucson News Now","url":"http:\/\/www.tucsonnewsnow.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/812\/normal\/Screen_Shot_2016-01-27_at_10.13.49.png?1453889665"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478506364&p=1pl&v=1&x=VPcGJKk44KwIEd54AJbE_g","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:50:00+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WFMJ","url":"http:\/\/www.wfmj.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/701\/normal\/Screen_Shot_2016-01-26_at_14.49.34.png?1453819812"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478510432&p=1pl&v=1&x=S5qxxoEH237H8T9bapw7_w","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:54:42+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WFLX Fox 29","url":"http:\/\/www.wflx.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/656\/normal\/Screen_Shot_2016-01-26_at_12.07.36.png?1453810094"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478513989&p=1pl&v=1&x=Z_GpNSvwL9Kh60ouijDPXw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:55:04+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KUSI News","url":"http:\/\/www.kusi.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/663\/normal\/Screen_Shot_2016-01-26_at_13.26.05.png?1453815145"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478521575&p=1pl&v=1&x=hanLpj88Cf9KqvCWNhttqw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:55:50+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"South Carolina News Now","url":"http:\/\/www.live5news.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/730\/normal\/Screen_Shot_2016-01-26_at_15.47.02.png?1453823263"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478531898&p=1pl&v=1&x=gSxLcJ2lRTknobZ1dJotsA","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:56:44+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KAIT-TV","url":"http:\/\/www.kait8.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/672\/normal\/Screen_Shot_2016-01-26_at_14.02.53.png?1453817085"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478555513&p=1pl&v=1&x=uVRZfjOzzY1HR2J8kneqFw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:59:26+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"Wave 3 News","url":"http:\/\/www.wave3.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/697\/normal\/Screen_Shot_2016-01-26_at_14.44.55.png?1453819521"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478576410&p=1pl&v=1&x=ZSv3XYPzfbBQkxC_FeD-5Q","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:01:28+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"NBC12","url":"http:\/\/www.nbc12.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/702\/normal\/Screen_Shot_2016-01-26_at_14.51.21.png?1453819926"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478581886&p=1pl&v=1&x=v4JIS3ThQWlp9_ZTeWWQaQ","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:01:53+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WMC Action News 5","url":"http:\/\/www.wmcactionnews5.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/727\/normal\/Screen_Shot_2016-01-26_at_15.42.23.png?1453822987"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478585429&p=1pl&v=1&x=ZU5RttW3WBCVQIxR1A_Jyw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:02:15+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KHQ","url":"http:\/\/www.khq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/658\/normal\/Screen_Shot_2016-01-26_at_12.10.14.png?1453810239"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478586897&p=1pl&v=1&x=kaZIMZ8o0_YjZ8qL-G85sA","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T10:01:25+00:00","summary":"LOS ANGELES, Nov. 2, 2016 \/PRNewswire-USNewswire\/ -- The International Myeloma Foundation (IMF) \u2013 improving the quality of life of myeloma patients while working toward prevention and a cure \u2013 is pleased to announce that the National Comprehensive\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478599967&p=1pl&v=1&x=QiPsLen8TeAt6GIOcd7tpw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:03:41+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KLKN-TV Eyewitness News","url":"http:\/\/www.klkntv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/655\/normal\/Screen_Shot_2016-01-26_at_12.06.08.png?1453810028"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478600416&p=1pl&v=1&x=NdGLjYFAAm2pskLPm6aTjQ","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:03:44+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KCBD","url":"http:\/\/www.kcbd.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/666\/normal\/Screen_Shot_2016-01-26_at_13.37.01.png?1453815461"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478608831&p=1pl&v=1&x=QQpqO7uupV5jDCig_JppuA","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:50:00+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"ABC 6 News WLNE","url":"http:\/\/www.abc6.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/712\/normal\/Screen_Shot_2016-01-26_at_15.16.08.png?1453821391"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478625914&p=1pl&v=1&x=vhNuw3meZK8k3YJKnDr5HA","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:06:17+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KLTV","url":"http:\/\/www.kltv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/704\/normal\/Screen_Shot_2016-01-26_at_14.54.15.png?1453820113"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478633060&p=1pl&v=1&x=v8duHFe-sB1IN3vS4yui-A","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:07:02+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"CW: Richmond","url":"http:\/\/www.cwrichmond.tv","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/648\/normal\/Screen_Shot_2016-01-26_at_11.48.33.png?1453809040"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478635617&p=1pl&v=1&x=mqnhrg_cfjx0wwAvYOMffQ","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:07:19+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"News 9","url":"http:\/\/www.news9.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/691\/normal\/Screen_Shot_2016-01-26_at_14.34.55.png?1453818924"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478638503&p=1pl&v=1&x=Fn1LVth9hMBoSN5dURdMGg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:07:37+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"ABC 7 News KSWO","url":"http:\/\/www.kswo.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/708\/normal\/Screen_Shot_2016-01-26_at_15.08.58.png?1453821021"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478638809&p=1pl&v=1&x=P1KwM9BhpFcL3_BpmqX8DQ","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:07:39+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WSFA ","url":"http:\/\/www.wsfa.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/644\/normal\/Screen_Shot_2016-01-26_at_11.40.39.png?1453808470"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478644670&p=1pl&v=1&x=MnMhNKoq3VnFjvH-rXns9Q","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:08:17+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"ABC 40","url":"http:\/\/www.abc40.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/698\/normal\/Screen_Shot_2016-01-26_at_14.45.46.png?1453819612"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478655451&p=1pl&v=1&x=AgxL3x5MlwYwE1WCbqei6A","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:09:31+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"NBC Right Now KNDU 25","url":"http:\/\/www.nbcrightnow.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/735\/normal\/Screen_Shot_2016-01-26_at_15.54.16.png?1453823699"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478656322&p=1pl&v=1&x=D8_w-Gp5jHgNXt0uVqZpMg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:50:00+00:00","summary":"Information contained on this page is provided by an independent third-party content provider.","author":{"name":"2 News","url":"http:\/\/www.ktvn.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/654\/normal\/Screen_Shot_2016-01-26_at_12.05.19.png?1453809947"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478662991&p=1pl&v=1&x=2hwc1BUpF9lxO08xDIYW3g","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:10:22+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WTVM","url":"http:\/\/www.wtvm.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/646\/normal\/Screen_Shot_2016-02-02_at_14.58.13.png?1454425111"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478675720&p=1pl&v=1&x=jkYp_PGAuLiBUhONTF_vFw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:50:00+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WISTV","url":"http:\/\/www.wistv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/689\/normal\/Screen_Shot_2016-01-26_at_14.30.56.png?1453818748"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478676641&p=1pl&v=1&x=_QnPxdrc0y3K3n3kMXDbHw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:11:46+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"14 News","url":"http:\/\/www.14news.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/696\/normal\/Screen_Shot_2016-01-26_at_14.43.50.png?1453819462"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478679100&p=1pl&v=1&x=-QoRUA0EjGrwRCihnMzpmg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:12:00+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"Hawaii News Now","url":"http:\/\/www.hawaiinewsnow.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/661\/normal\/Screen_Shot_2016-01-26_at_12.16.42.png?1453810633"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478692970&p=1pl&v=1&x=1Op656dy5qmlFXjUTY4j1w","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:13:33+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WDAM - TV","url":"http:\/\/www.wdam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/682\/normal\/Screen_Shot_2016-01-26_at_14.19.46.png?1453818016"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478696200&p=1pl&v=1&x=F6p9ooN3gnOhr0vqlAIUgg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:13:54+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"Mississippi News Now ","url":"http:\/\/www.msnewsnow.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/649\/normal\/Screen_Shot_2016-01-26_at_11.57.00.png?1453809440"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478696791&p=1pl&v=1&x=WmtyV_jLzbeAaTCzGB_Peg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:50:00+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WALB","url":"http:\/\/www.walb.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/647\/normal\/Screen_Shot_2016-01-26_at_11.47.02.png?1453808851"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478697591&p=1pl&v=1&x=0pq4cBqgOFTxNc93-ZzYqg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:14:04+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KSLA News 12","url":"http:\/\/www.ksla.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/709\/normal\/Screen_Shot_2016-01-26_at_15.10.50.png?1453821079"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478697812&p=1pl&v=1&x=xv4JuZNYMtYTUaBk4tT7Og","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:14:05+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"Cleveland 19","url":"http:\/\/www.cleveland19.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/683\/normal\/Screen_Shot_2016-01-26_at_14.20.50.png?1453818081"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478700907&p=1pl&v=1&x=It9SvvlYRsZeoEw-PUm52g","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:14:26+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WLTZ","url":"http:\/\/www.wltz.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/653\/normal\/Screen_Shot_2016-01-26_at_12.04.16.png?1453809879"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478703650&p=1pl&v=1&x=I7SiaF0gc7q3em5R6yisnQ","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:14:44+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"NewsWest9","url":"http:\/\/www.newswest9.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/703\/normal\/Screen_Shot_2016-01-26_at_14.52.45.png?1453820009"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478715147&p=1pl&v=1&x=NFzlcNXDEE6CjSeWSv2W3w","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:16:02+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"Fox Wilmington","url":"http:\/\/www.wsfx.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/740\/normal\/Screen_Shot_2016-01-26_at_16.09.52.png?1453824618"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478732924&p=1pl&v=1&x=5dwEaZhJfm7bosjuSv6Oyg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:17:56+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"News Channel 6","url":"http:\/\/www.newschannel6now.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/652\/normal\/Screen_Shot_2016-01-26_at_12.01.23.png?1453809711"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478753463&p=1pl&v=1&x=Muvyobc-Jn2TctH0tytqDQ","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:20:15+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WTOL","url":"http:\/\/www.wtol.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/662\/normal\/Screen_Shot_2016-01-26_at_12.19.14.png?1453810785"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478755020&p=1pl&v=1&x=KSFJb_O8sVofJBEl-eoixw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:50:00+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WAND 17","url":"http:\/\/www.wandtv.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/694\/normal\/Screen_Shot_2016-01-26_at_14.41.02.png?1453819294"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478757944&p=1pl&v=1&x=6IwdNsXGFpHwkWS2c8IXng","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:20:41+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WLOX","url":"http:\/\/www.wlox.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/657\/normal\/Screen_Shot_2016-01-26_at_12.08.48.png?1453810156"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478759941&p=1pl&v=1&x=E7IuY1UjRt-KiGmWWUOLsw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:20:52+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WDRB","url":"http:\/\/www.wdrb.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/693\/normal\/Screen_Shot_2016-01-26_at_14.37.05.png?1453819066"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478763218&p=1pl&v=1&x=w9xvf5KUFvzOAzVQWOvN0Q","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T13:50:00+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"News Channel","url":"http:\/\/www.kxxv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/645\/normal\/Screen_Shot_2016-01-26_at_11.42.27.png?1453808595"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478769578&p=1pl&v=1&x=1hee4HZtQi9EEo8QpN146w","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:22:00+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"NewsOn6","url":"http:\/\/www.newson6.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/677\/normal\/Screen_Shot_2016-01-26_at_14.12.15.png?1453817572"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478785227&p=1pl&v=1&x=PPtnk2c3qY0vj7sHa5LPgw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:23:45+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"Kuam","url":"http:\/\/www.kuam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/667\/normal\/Screen_Shot_2016-01-26_at_13.48.34.png?1453816300"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478788757&p=1pl&v=1&x=rzIeLeQvcChbXlS9MjPPOA","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:24:11+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WMBF News","url":"http:\/\/www.wmbfnews.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/710\/normal\/Screen_Shot_2016-01-26_at_15.11.39.png?1453821128"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478806778&p=1pl&v=1&x=WAr88aRQnALAUaqctBdiaw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:26:06+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"WRCB- TV","url":"http:\/\/www.wrcbtv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/690\/normal\/Screen_Shot_2016-01-26_at_14.32.42.png?1453818828"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478855327&p=1pl&v=1&x=gB2ijUHAH_CofN9XYgB_Yw","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:31:16+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KTEN","url":"http:\/\/www.kten.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/643\/normal\/Screen_Shot_2016-01-26_at_11.36.58.png?1453808251"}},{"title":"International Myeloma Working Group's New Response Criteria Prompts NCCN to Revise Practice Guidelines to Include Minimal Residual Disease (MRD) Testing","url":"http:\/\/ct.moreover.com\/?a=28478875845&p=1pl&v=1&x=Pso0hKI5CmC_vBZUUflZHg","license":"public","citation_ids":[10065061],"posted_on":"2016-11-02T14:33:15+00:00","summary":"SOURCE International Myeloma Foundation Action Underscores Value of MRD Assessment in Multiple Myeloma LOS ANGELES The NCCN is a nonprofit alliance of cancer centers that develops practice guidelines to help physicians in making informed treatment\u2026","author":{"name":"KTRE","url":"http:\/\/www.ktre.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/705\/normal\/Screen_Shot_2016-01-26_at_15.04.21.png?1453820750"}}],"twitter":[{"url":"http:\/\/twitter.com\/elfarodehuse\/statuses\/758240263244541952","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-27T09:59:00+00:00","author":{"name":"Farmacia Son Espases","url":"http:\/\/www.elcomprimido.com\/FARHSD\/PORTAL.htm","image":"https:\/\/pbs.twimg.com\/profile_images\/588395465592479746\/N5eycZR3_normal.png","description":"Servicio de Farmacia Hospital Son Espases [antes Son Dureta...]","id_on_source":"elfarodehuse","tweeter_id":"3020154741","geo":{"lt":39.56951,"ln":2.64745,"country":"ES"},"followers":1530},"tweet_id":"758240263244541952"},{"url":"http:\/\/twitter.com\/VincentRK\/statuses\/758277586057256962","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-27T12:27:19+00:00","author":{"name":"Vincent Rajkumar","url":"http:\/\/bit.ly\/Z4PHPv","image":"https:\/\/pbs.twimg.com\/profile_images\/3418263560\/a40cbe1b5676b01dff5a8eb86e87c099_normal.jpeg","description":"Edward W & Betty Knight Scripps Professor, Mayo Clinic; Editor, Blood Cancer J; Assoc Editor, Mayo Clin Proceedings; No Financial COI http:\/\/tinyurl.com\/houbsqb","id_on_source":"VincentRK","tweeter_id":"24261916","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":5435},"tweet_id":"758277586057256962"},{"url":"http:\/\/twitter.com\/IMFmyeloma\/statuses\/758278471332171776","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T12:30:50+00:00","author":{"name":"IMF - Myeloma.org","url":"http:\/\/www.myeloma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/851822555472302080\/b1jZjs6M_normal.jpg","description":"Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.","id_on_source":"IMFmyeloma","tweeter_id":"34340707","geo":{"lt":34.17223,"ln":-118.37897,"country":"US"},"followers":6684},"tweet_id":"758278471332171776"},{"url":"http:\/\/twitter.com\/bhemato\/statuses\/758279674032189440","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T12:35:37+00:00","author":{"name":"Binod Dhakal","image":"https:\/\/pbs.twimg.com\/profile_images\/506637496654901248\/bTIOp3tv_normal.jpeg","description":"MCW Faculty. Myeloma. Lymphoma and Clinical trials.","id_on_source":"bhemato","tweeter_id":"2783218747","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":292},"tweet_id":"758279674032189440"},{"url":"http:\/\/twitter.com\/fifyfo\/statuses\/758281995050971136","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T12:44:50+00:00","author":{"name":"NewNessofLyf","image":"https:\/\/pbs.twimg.com\/profile_images\/852811683491758080\/s9GUE_jB_normal.jpg","description":"LoveRules, JesusLives, LoveScandal, LoveLife","id_on_source":"fifyfo","tweeter_id":"32888783","geo":{"lt":null,"ln":null},"followers":427},"tweet_id":"758281995050971136"},{"url":"http:\/\/twitter.com\/Cytognos\/statuses\/758282514431705088","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T12:46:54+00:00","author":{"name":"Cytognos","url":"http:\/\/www.cytognos.com","image":"https:\/\/pbs.twimg.com\/profile_images\/435317300539846656\/xV6dyojn_normal.png","description":"Biotechnology company dedicated to the design and development of reagents and software in the flow cytometry field. EuroFlow\u2122 Supporting Company","id_on_source":"Cytognos","tweeter_id":"484698843","geo":{"lt":40.96882,"ln":-5.66388,"country":"ES"},"followers":524},"tweet_id":"758282514431705088"},{"url":"http:\/\/twitter.com\/glorinharegina\/statuses\/758285795228839940","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T12:59:56+00:00","author":{"name":"Gloria Regina Souza","image":"https:\/\/pbs.twimg.com\/profile_images\/904761624073994241\/zXky3wpV_normal.jpg","id_on_source":"glorinharegina","tweeter_id":"231616529","geo":{"lt":null,"ln":null},"followers":117},"tweet_id":"758285795228839940"},{"url":"http:\/\/twitter.com\/MayoMyeloma\/statuses\/758295376415850496","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T13:38:00+00:00","author":{"name":"Mayo Myeloma","url":"http:\/\/www.msmart.org","image":"https:\/\/pbs.twimg.com\/profile_images\/132886714\/Myeloma_normal.jpg","description":"Vincent Rajkumar, MD, Professor of Medicine, on behalf of the Mayo Clinic Myeloma Group","id_on_source":"MayoMyeloma","tweeter_id":"30386069","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":4795},"tweet_id":"758295376415850496"},{"url":"http:\/\/twitter.com\/ChrisBoatner\/statuses\/758296193017516033","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T13:41:15+00:00","author":{"name":"BMTRegNurse","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000833482537\/29c983490629b426277863f4b2b92fb3_normal.jpeg","id_on_source":"ChrisBoatner","tweeter_id":"2209162186","geo":{"lt":33.47097,"ln":-81.97484,"country":"US"},"followers":56},"tweet_id":"758296193017516033"},{"url":"http:\/\/twitter.com\/hemaoncol\/statuses\/758296943189557248","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T13:44:14+00:00","author":{"name":"hema","image":"https:\/\/pbs.twimg.com\/profile_images\/699247941148479489\/cjvTjf_X_normal.jpg","id_on_source":"hemaoncol","tweeter_id":"4911657145","geo":{"lt":null,"ln":null},"followers":3},"tweet_id":"758296943189557248"},{"url":"http:\/\/twitter.com\/nbferrara\/statuses\/758316126711447556","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-27T15:00:28+00:00","author":{"name":"Nicole Ferrara","url":"http:\/\/www.mayoclinic.org\/mayo-clinic-cancer-center\/","image":"https:\/\/pbs.twimg.com\/profile_images\/742713261938769920\/XBfBOhYa_normal.jpg","description":"Senior Communications Specialist, Mayo Clinic Cancer Center. ADHD and mental health advocate. Opinions tweeted all mine. Get your own.","id_on_source":"nbferrara","tweeter_id":"344053705","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":1574},"tweet_id":"758316126711447556"},{"url":"http:\/\/twitter.com\/pharmaNGS\/statuses\/758317643438981120","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-27T15:06:29+00:00","author":{"name":"David Soong","image":"https:\/\/pbs.twimg.com\/profile_images\/2861189053\/b23aa64edc93d44d2c901b2a888d925a_normal.jpeg","description":"Computational biologist. Next-gen sequencing, cancer genomics, epigenetics, immunotherapy, drug repositioning\/discovery\/development, pharmaceutical industry.","id_on_source":"pharmaNGS","tweeter_id":"896595900","geo":{"lt":null,"ln":null},"followers":255},"tweet_id":"758317643438981120"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/758328100635762688","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T15:48:02+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"758328100635762688"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/758328158886170625","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-27T15:48:16+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"758328158886170625"},{"url":"http:\/\/twitter.com\/ClinOncNews\/statuses\/758329211551711234","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-07-27T15:52:27+00:00","author":{"name":"ClinicalOncologyNews","url":"http:\/\/www.clinicaloncology.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1896943910\/ClinOnc_MobileApp_Thumbnail_normal.jpg","description":"An independent source of unbiased, accurate, reliable news and in-depth expert analysis on issues oncologists and hematologist\/oncologists care about most.","id_on_source":"ClinOncNews","tweeter_id":"524587400","geo":{"lt":40.71427,"ln":-74.00597,"country":"US"},"followers":2150},"tweet_id":"758329211551711234"},{"url":"http:\/\/twitter.com\/DrAnasYounes\/statuses\/758338800783396865","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T16:30:34+00:00","author":{"name":"Anas Younes, M.D.","url":"http:\/\/www.mskcc.org\/cancer-care\/doctor\/anas-younes","image":"https:\/\/pbs.twimg.com\/profile_images\/691262343410491393\/MMchoo2v_normal.jpg","description":"Lymphoma expert, and Professor of Medicine at MSKCC. I tweet on lymphoma, medicine, cancer & health. Tweets and opinions are mine. RT and favorite = look","id_on_source":"DrAnasYounes","tweeter_id":"23631835","geo":{"lt":40.71427,"ln":-74.00597,"country":"US"},"followers":15453},"tweet_id":"758338800783396865"},{"url":"http:\/\/twitter.com\/MayoClinic\/statuses\/758342521672110081","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-27T16:45:21+00:00","author":{"name":"Mayo Clinic","url":"http:\/\/mayocl.in\/web","image":"https:\/\/pbs.twimg.com\/profile_images\/878347163272486912\/ktSje-hR_normal.jpg","description":"An integrated clinical practice, education and research institution specializing in treating patients. Account maintained by @MayoClinic\/MCCSM.","id_on_source":"MayoClinic","tweeter_id":"14592723","geo":{"lt":null,"ln":null},"followers":1705595},"tweet_id":"758342521672110081"},{"url":"http:\/\/twitter.com\/Utopain\/statuses\/758342788702433282","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-27T16:46:24+00:00","author":{"name":"Ho-Young Yhim","image":"https:\/\/pbs.twimg.com\/profile_images\/568934471588515840\/D01PSZv5_normal.jpeg","description":"\u76f2\u4eba\u6478\u8c61 (\ub9f9\uc778\ubaa8\uc0c1)","id_on_source":"Utopain","tweeter_id":"88596085","geo":{"lt":37,"ln":127.5,"country":"KR"},"followers":57},"tweet_id":"758342788702433282"},{"url":"http:\/\/twitter.com\/DrSarahBHealthy\/statuses\/758343096534958080","license":"gnip","rt":["MayoClinic"],"citation_ids":[10065061],"posted_on":"2016-07-27T16:47:38+00:00","author":{"name":"Dr Sarah Brewer","url":"http:\/\/www.DrSarahBrewer.com","image":"https:\/\/pbs.twimg.com\/profile_images\/705157499134058496\/1LAhUW33_normal.jpg","description":"Interesting health & fitness news, facts, tips and advice. For #nutrition & #recipes see @DrSarahB","id_on_source":"DrSarahBHealthy","tweeter_id":"3438131158","geo":{"lt":54.75844,"ln":-2.69531,"country":"GB"},"followers":43205},"tweet_id":"758343096534958080"},{"url":"http:\/\/twitter.com\/TheScientifiK\/statuses\/758343600728047617","license":"gnip","rt":["MayoClinic"],"citation_ids":[10065061],"posted_on":"2016-07-27T16:49:38+00:00","author":{"name":"The ScientifiK","url":"http:\/\/www.thescientifik.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1592720178\/27507_thumb125_normal.jpg","description":"Healthcare | Patients | Technology | Treatment | Therapy | Physician | Payor | Internet | Lifestyle","id_on_source":"TheScientifiK","tweeter_id":"170400197","geo":{"lt":37.56299,"ln":-122.32553,"country":"US"},"followers":81993},"tweet_id":"758343600728047617"},{"url":"http:\/\/twitter.com\/mustafaalid\/statuses\/758347135284838401","license":"gnip","rt":["MayoClinic"],"citation_ids":[10065061],"posted_on":"2016-07-27T17:03:41+00:00","author":{"name":"mustafa ali dabwan","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000450949223\/54577d826e05618c70710cefa1cc793d_normal.jpeg","id_on_source":"mustafaalid","tweeter_id":"782517746","geo":{"lt":null,"ln":null},"followers":48},"tweet_id":"758347135284838401"},{"url":"http:\/\/twitter.com\/MRISoundImaging\/statuses\/758347926716416001","license":"gnip","rt":["MayoClinic"],"citation_ids":[10065061],"posted_on":"2016-07-27T17:06:49+00:00","author":{"name":"Sound Imaging","url":"http:\/\/www.soundimaginginc.com","image":"https:\/\/pbs.twimg.com\/profile_images\/589205703278993408\/ZsNhVV4N_normal.jpg","description":"Sound Imaging specializes in MRI parts, MRI coils, MRI service and MRI accessories for both mobile MRI and fixed sites.","id_on_source":"MRISoundImaging","tweeter_id":"2447976744","geo":{"lt":null,"ln":null},"followers":300},"tweet_id":"758347926716416001"},{"url":"http:\/\/twitter.com\/VincentRK\/statuses\/758363847405080576","license":"gnip","rt":["MayoClinic"],"citation_ids":[10065061],"posted_on":"2016-07-27T18:10:05+00:00","author":{"name":"Vincent Rajkumar","url":"http:\/\/bit.ly\/Z4PHPv","image":"https:\/\/pbs.twimg.com\/profile_images\/3418263560\/a40cbe1b5676b01dff5a8eb86e87c099_normal.jpeg","description":"Edward W & Betty Knight Scripps Professor, Mayo Clinic; Editor, Blood Cancer J; Assoc Editor, Mayo Clin Proceedings; No Financial COI http:\/\/tinyurl.com\/houbsqb","id_on_source":"VincentRK","tweeter_id":"24261916","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":5435},"tweet_id":"758363847405080576"},{"url":"http:\/\/twitter.com\/MyGood_Health1\/statuses\/758364484826042368","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-27T18:12:37+00:00","author":{"name":"Dr. Brandon","image":"https:\/\/pbs.twimg.com\/profile_images\/698823812289208320\/k361l2Z9_normal.jpg","description":"It is #health that is real #wealth and not pieces of gold and silver. #Follow Me","id_on_source":"MyGood_Health1","tweeter_id":"4717298733","geo":{"lt":null,"ln":null},"followers":954},"tweet_id":"758364484826042368"},{"url":"http:\/\/twitter.com\/NicoleRdcs\/statuses\/758390115521662976","license":"gnip","rt":["MayoClinic"],"citation_ids":[10065061],"posted_on":"2016-07-27T19:54:28+00:00","author":{"name":"Nicole Zafiris,RDCS","image":"https:\/\/pbs.twimg.com\/profile_images\/770984616052260864\/W49ekDJ__normal.jpg","description":"Registered Echocardiographer","id_on_source":"NicoleRdcs","tweeter_id":"3873945628","geo":{"lt":null,"ln":null},"followers":49},"tweet_id":"758390115521662976"},{"url":"http:\/\/twitter.com\/glorinharegina\/statuses\/758395195159408640","license":"gnip","rt":["MayoClinic"],"citation_ids":[10065061],"posted_on":"2016-07-27T20:14:39+00:00","author":{"name":"Gloria Regina Souza","image":"https:\/\/pbs.twimg.com\/profile_images\/904761624073994241\/zXky3wpV_normal.jpg","id_on_source":"glorinharegina","tweeter_id":"231616529","geo":{"lt":null,"ln":null},"followers":117},"tweet_id":"758395195159408640"},{"url":"http:\/\/twitter.com\/pvlummen\/statuses\/758429687102275584","license":"gnip","rt":["MayoClinic"],"citation_ids":[10065061],"posted_on":"2016-07-27T22:31:43+00:00","author":{"name":"Philip Vlummens","image":"https:\/\/pbs.twimg.com\/profile_images\/698436984906326016\/FKMLuEPO_normal.jpg","description":"Go player, husband and father","id_on_source":"pvlummen","tweeter_id":"331449090","geo":{"lt":50.83333,"ln":4,"country":"BE"},"followers":107},"tweet_id":"758429687102275584"},{"url":"http:\/\/twitter.com\/hazim20014\/statuses\/758435932672561152","license":"gnip","rt":["MayoClinic"],"citation_ids":[10065061],"posted_on":"2016-07-27T22:56:32+00:00","author":{"name":"mohammed","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_3_normal.png","id_on_source":"hazim20014","tweeter_id":"2359869361","geo":{"lt":null,"ln":null},"followers":78},"tweet_id":"758435932672561152"},{"url":"http:\/\/twitter.com\/FarmaOnco\/statuses\/758517419178590208","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-28T04:20:19+00:00","author":{"name":"FarmaOnco","image":"https:\/\/pbs.twimg.com\/profile_images\/2930931336\/c5ed1efcf9ddf36d4803c1ab88604f4f_normal.jpeg","description":"Farmac\u00e9utica hospitalaria que intenta mantenerse al d\u00eda en onco, hemato y otras cosas","id_on_source":"FarmaOnco","tweeter_id":"917639060","geo":{"lt":null,"ln":null},"followers":1686},"tweet_id":"758517419178590208"},{"url":"http:\/\/twitter.com\/dzivalj\/statuses\/758563530626965505","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-28T07:23:33+00:00","author":{"name":"Dinka \u017divalj","url":"http:\/\/www.linkedin.com\/pub\/dinka-zivalj\/38\/b44\/b11","image":"https:\/\/pbs.twimg.com\/profile_images\/782196239429472256\/q8iugh2e_normal.jpg","description":"Komunikacije, mediji, pol., EU, me\u0111. odnosi. Communication, pol. affairs, media dev., EU & intl. relations. Head of Com\/Spokesperson, #EU #Kosovo. Pers. tweets.","id_on_source":"dzivalj","tweeter_id":"2472741882","geo":{"lt":45.81444,"ln":15.97798,"country":"HR"},"followers":241},"tweet_id":"758563530626965505"},{"url":"http:\/\/twitter.com\/paulajgt\/statuses\/758577488490532864","license":"gnip","rt":["elfarodehuse"],"citation_ids":[10065061],"posted_on":"2016-07-28T08:19:01+00:00","author":{"name":"Paula de Juan-Garc\u00eda","image":"https:\/\/pbs.twimg.com\/profile_images\/3477467407\/3d51cbf7500161b6fc0344dadf75ff97_normal.jpeg","description":"Farmaceutica de hospital dedicada a la Farmacia Oncol\u00f3gica.","id_on_source":"paulajgt","tweeter_id":"1234530366","geo":{"lt":null,"ln":null},"followers":210},"tweet_id":"758577488490532864"},{"url":"http:\/\/twitter.com\/TheLancetOncol\/statuses\/758583814364987392","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-28T08:44:09+00:00","author":{"name":"The Lancet Oncology","url":"http:\/\/www.thelancet.com","image":"https:\/\/pbs.twimg.com\/profile_images\/441608748306423808\/qlozKasq_normal.jpeg","description":"The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality, peer-reviewed research and reviews, comment, news, and Commissions.","id_on_source":"TheLancetOncol","tweeter_id":"50265238","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":11995},"tweet_id":"758583814364987392"},{"url":"http:\/\/twitter.com\/CancerWallonia\/statuses\/758588109655244800","license":"gnip","rt":["TheLancetOncol"],"citation_ids":[10065061],"posted_on":"2016-07-28T09:01:13+00:00","author":{"name":"CancerWallonia","image":"https:\/\/pbs.twimg.com\/profile_images\/623178120615604224\/unGEOij0_normal.jpg","description":"Cancer: from Wallonia to the World, from the World to Wallonia -  Cancer: la Wallonie parle au Monde, le Monde parle \u00e0 la Wallonie","id_on_source":"CancerWallonia","tweeter_id":"2848852120","geo":{"lt":null,"ln":null},"followers":635},"tweet_id":"758588109655244800"},{"url":"http:\/\/twitter.com\/TheBindingSite\/statuses\/758588164537782272","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-28T09:01:26+00:00","author":{"name":"Binding Site","url":"http:\/\/www.bindingsite.com","image":"https:\/\/pbs.twimg.com\/profile_images\/469051367084916736\/1pkG_IwD_normal.jpeg","description":"Specialist Protein Company - Committed to improving patient lives worldwide through education, collaboration & innovation. Disclaimer http:\/\/hub.am\/1nolDUW","id_on_source":"TheBindingSite","tweeter_id":"321436678","geo":{"lt":null,"ln":null},"followers":632},"tweet_id":"758588164537782272"},{"url":"http:\/\/twitter.com\/BindingSiteHaem\/statuses\/758588204597542912","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-28T09:01:36+00:00","author":{"name":"Binding Site","url":"http:\/\/www.bindingsite.com","image":"https:\/\/pbs.twimg.com\/profile_images\/466145479625949187\/lZH6z1lj_normal.png","description":"Clinical utility of free light chains (Freelite) & heavy\/light chains (Hevylite) in monoclonal gammopathy #myeloma #nephrology Disclaimer http:\/\/hub.am\/1jLoIuK","id_on_source":"BindingSiteHaem","tweeter_id":"875434993","geo":{"lt":52.48142,"ln":-1.89983,"country":"GB"},"followers":827},"tweet_id":"758588204597542912"},{"url":"http:\/\/twitter.com\/gwenniejacques\/statuses\/758591335423180800","license":"gnip","rt":["TheLancetOncol"],"citation_ids":[10065061],"posted_on":"2016-07-28T09:14:02+00:00","author":{"name":"Gwen Jacques","image":"https:\/\/pbs.twimg.com\/profile_images\/858642412708777984\/4pjNPoia_normal.jpg","id_on_source":"gwenniejacques","tweeter_id":"211603945","geo":{"lt":53.79648,"ln":-1.54785,"country":"GB"},"followers":619},"tweet_id":"758591335423180800"},{"url":"http:\/\/twitter.com\/TiengJackie\/statuses\/758624122633019392","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-28T11:24:20+00:00","author":{"name":"Jackie Tieng, PH\/MBA","image":"https:\/\/pbs.twimg.com\/profile_images\/721768828007374848\/ZrxHKM1Y_normal.jpg","description":"Life..Life..Life..full of Surprise.. Stay Hungry, Stay Foolish.. Live is Hope, Never Never Give UP...","id_on_source":"TiengJackie","tweeter_id":"721279245842915328","geo":{"lt":24,"ln":121,"country":"TW"},"followers":8},"tweet_id":"758624122633019392"},{"url":"http:\/\/twitter.com\/beatl51\/statuses\/758649534129987584","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-07-28T13:05:18+00:00","author":{"name":"Sukjoong Oh","image":"https:\/\/pbs.twimg.com\/profile_images\/546851145092579328\/JXWGqNol_normal.jpeg","description":"Professor, Kangbuk Samsung Hospital,\nSungkyunkwan University, Seoul #hematology # GI oncology","id_on_source":"beatl51","tweeter_id":"194779262","geo":{"lt":null,"ln":null},"followers":65},"tweet_id":"758649534129987584"},{"url":"http:\/\/twitter.com\/jose6xxx\/statuses\/758655463089172480","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-28T13:28:52+00:00","author":{"name":"Jos\u00e9 L. Garc\u00eda","url":"https:\/\/es.linkedin.com\/in\/jose0","image":"https:\/\/pbs.twimg.com\/profile_images\/610876993354264577\/iveN_9iL_normal.jpg","description":"Especialista en Bioqu\u00edmica Cl\u00ednica y An\u00e1lisis Cl\u00ednicos. Complejo Hospitalario Universitario de Granada","id_on_source":"jose6xxx","tweeter_id":"406496525","geo":{"lt":40,"ln":-4,"country":"ES"},"followers":495},"tweet_id":"758655463089172480"},{"url":"http:\/\/twitter.com\/VincentRK\/statuses\/758686821869981696","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-07-28T15:33:28+00:00","author":{"name":"Vincent Rajkumar","url":"http:\/\/bit.ly\/Z4PHPv","image":"https:\/\/pbs.twimg.com\/profile_images\/3418263560\/a40cbe1b5676b01dff5a8eb86e87c099_normal.jpeg","description":"Edward W & Betty Knight Scripps Professor, Mayo Clinic; Editor, Blood Cancer J; Assoc Editor, Mayo Clin Proceedings; No Financial COI http:\/\/tinyurl.com\/houbsqb","id_on_source":"VincentRK","tweeter_id":"24261916","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":5435},"tweet_id":"758686821869981696"},{"url":"http:\/\/twitter.com\/ONKOSconsulting\/statuses\/758780218970693632","license":"gnip","rt":["TheLancetOncol"],"citation_ids":[10065061],"posted_on":"2016-07-28T21:44:36+00:00","author":{"name":"ONKOS Consulting","image":"https:\/\/pbs.twimg.com\/profile_images\/579978338049138688\/RqlopOAX_normal.png","id_on_source":"ONKOSconsulting","tweeter_id":"3107537152","geo":{"lt":null,"ln":null},"followers":29},"tweet_id":"758780218970693632"},{"url":"http:\/\/twitter.com\/szusmani\/statuses\/758837706147241984","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-29T01:33:02+00:00","author":{"name":"Saad Usmani","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000183096480\/a59c3a441593739eceb443f5e7bbfda7_normal.jpeg","description":"Chief, Plasma Cell Disorders; Director, Clinical Research in Hem Malignancies (Levine Cancer Institute). Clinician, researcher, cricket fan, views are my own","id_on_source":"szusmani","tweeter_id":"83911786","geo":{"lt":35.22709,"ln":-80.84313,"country":"US"},"followers":1961},"tweet_id":"758837706147241984"},{"url":"http:\/\/twitter.com\/IMFmyeloma\/statuses\/758839858487922689","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-29T01:41:35+00:00","author":{"name":"IMF - Myeloma.org","url":"http:\/\/www.myeloma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/851822555472302080\/b1jZjs6M_normal.jpg","description":"Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.","id_on_source":"IMFmyeloma","tweeter_id":"34340707","geo":{"lt":34.17223,"ln":-118.37897,"country":"US"},"followers":6684},"tweet_id":"758839858487922689"},{"url":"http:\/\/twitter.com\/Transplant_Doc\/statuses\/758845375528611840","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-29T02:03:30+00:00","author":{"name":"Muzaffar Qazilbash","url":"http:\/\/faculty.mdanderson.org\/Muzaffar_Qazilbash\/Default.asp","image":"https:\/\/pbs.twimg.com\/profile_images\/1805143659\/Profile_compressed_pic-_020412_normal.jpg","description":"Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own","id_on_source":"Transplant_Doc","tweeter_id":"162587280","geo":{"lt":null,"ln":null},"followers":3421},"tweet_id":"758845375528611840"},{"url":"http:\/\/twitter.com\/marinellopatri\/statuses\/758853527284305927","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-29T02:35:54+00:00","author":{"name":"Patricia Marinello","image":"https:\/\/pbs.twimg.com\/profile_images\/728692449770668032\/GU255OOV_normal.jpg","description":"Your regular cuban chick with a passion for cancer research","id_on_source":"marinellopatri","tweeter_id":"726687600459833344","geo":{"lt":39.95234,"ln":-75.16379,"country":"US"},"followers":32},"tweet_id":"758853527284305927"},{"url":"http:\/\/twitter.com\/M_E_Atiya\/statuses\/758859841192341504","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-29T03:00:59+00:00","author":{"name":"Mohammad Atiya","image":"https:\/\/pbs.twimg.com\/profile_images\/819000673333297154\/vciYAsEJ_normal.jpg","id_on_source":"M_E_Atiya","tweeter_id":"2503374718","geo":{"lt":null,"ln":null},"followers":76},"tweet_id":"758859841192341504"},{"url":"http:\/\/twitter.com\/psharmaMD\/statuses\/758875315552735232","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-29T04:02:29+00:00","author":{"name":"Prashant Sharma","image":"https:\/\/pbs.twimg.com\/profile_images\/578755722067861504\/64G4FrW6_normal.jpeg","description":"Hem\/Onc fellow at University of Colorado. Prior hospitalist at Mayo and Cleveland Clinics. Views are mine.","id_on_source":"psharmaMD","tweeter_id":"3018932371","geo":{"lt":39.73915,"ln":-104.9847,"country":"US"},"followers":82},"tweet_id":"758875315552735232"},{"url":"http:\/\/twitter.com\/alantanmd\/statuses\/758883985728544770","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-29T04:36:56+00:00","author":{"name":"Dr. Alan Tan","url":"http:\/\/www.cancercenter.com\/western\/doctors-and-clinicians\/alan-tan\/","image":"https:\/\/pbs.twimg.com\/profile_images\/825481085907644416\/yFjMphtj_normal.jpg","description":"Director of Hematologic Malignancies and Cancer Immunotherapy","id_on_source":"alantanmd","tweeter_id":"44852210","geo":{"lt":33.44838,"ln":-112.07404,"country":"US"},"followers":874},"tweet_id":"758883985728544770"},{"url":"http:\/\/twitter.com\/VJHemOnc\/statuses\/758885785378496512","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-29T04:44:05+00:00","author":{"name":"VJHemOnc","url":"http:\/\/www.vjhemonc.com","image":"https:\/\/pbs.twimg.com\/profile_images\/725270166603464704\/v5CYY83F_normal.jpg","description":"Video Journal of Hematological Oncology is dedicated to providing trusted information, to improve knowledge, understanding and awareness of hematological cancer","id_on_source":"VJHemOnc","tweeter_id":"3187500729","geo":{"lt":null,"ln":null},"followers":2233},"tweet_id":"758885785378496512"},{"url":"http:\/\/twitter.com\/akeithstewart\/statuses\/758924089616576513","license":"gnip","rt":["TheLancetOncol"],"citation_ids":[10065061],"posted_on":"2016-07-29T07:16:17+00:00","author":{"name":"Keith Stewart","image":"https:\/\/pbs.twimg.com\/profile_images\/827006382066896897\/aSYFUXAV_normal.jpg","id_on_source":"akeithstewart","tweeter_id":"2237978442","geo":{"lt":null,"ln":null},"followers":1132},"tweet_id":"758924089616576513"},{"url":"http:\/\/twitter.com\/Aurora_Cancer\/statuses\/758964163678916612","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-29T09:55:32+00:00","author":{"name":"Aurora Cancer Care","url":"https:\/\/www.aurorahealthcare.org\/services\/cancer","image":"https:\/\/pbs.twimg.com\/profile_images\/510102625086210048\/qnjNLC3v_normal.jpeg","description":"Aurora Cancer Care - part of @Aurora_Health","id_on_source":"Aurora_Cancer","tweeter_id":"2727758072","geo":{"lt":40.00032,"ln":-89.25037,"country":"US"},"followers":439},"tweet_id":"758964163678916612"},{"url":"http:\/\/twitter.com\/dianis_nm\/statuses\/758998956055506948","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-29T12:13:47+00:00","author":{"name":"Diana","image":"https:\/\/pbs.twimg.com\/profile_images\/913028657509052416\/RT3gjF-G_normal.jpg","description":"Hemat\u00f3loga \ud83d\udd2c\ud83d\udc96","id_on_source":"dianis_nm","tweeter_id":"455457293","geo":{"lt":17.07108,"ln":-96.71914,"country":"MX"},"followers":399},"tweet_id":"758998956055506948"},{"url":"http:\/\/twitter.com\/MyelomaTeacher\/statuses\/759052397939269632","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-29T15:46:08+00:00","author":{"name":"Myeloma Teacher","url":"http:\/\/facebook.com\/myelomateacher","image":"https:\/\/pbs.twimg.com\/profile_images\/717171403745832960\/Mcrsrp6c_normal.jpg","description":"Advocate, Ambassador & Mentor, Patient Services Volunteer, @Ash_hematology Speaker, Myeloma Survivor, IRB Member, @CureForward PMA #MMSM #ePatient #canserve","id_on_source":"MyelomaTeacher","tweeter_id":"32530883","geo":{"lt":40.29733,"ln":-74.7296,"country":"US"},"followers":5341},"tweet_id":"759052397939269632"},{"url":"http:\/\/twitter.com\/VincentRK\/statuses\/759052486741078016","license":"gnip","rt":["MyelomaTeacher"],"citation_ids":[10065061],"posted_on":"2016-07-29T15:46:30+00:00","author":{"name":"Vincent Rajkumar","url":"http:\/\/bit.ly\/Z4PHPv","image":"https:\/\/pbs.twimg.com\/profile_images\/3418263560\/a40cbe1b5676b01dff5a8eb86e87c099_normal.jpeg","description":"Edward W & Betty Knight Scripps Professor, Mayo Clinic; Editor, Blood Cancer J; Assoc Editor, Mayo Clin Proceedings; No Financial COI http:\/\/tinyurl.com\/houbsqb","id_on_source":"VincentRK","tweeter_id":"24261916","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":5435},"tweet_id":"759052486741078016"},{"url":"http:\/\/twitter.com\/ACCCBuzz\/statuses\/759052663149375488","license":"gnip","rt":["MyelomaTeacher"],"citation_ids":[10065061],"posted_on":"2016-07-29T15:47:12+00:00","author":{"name":"ACCC","url":"http:\/\/www.accc-cancer.org","image":"https:\/\/pbs.twimg.com\/profile_images\/527125027473199104\/8olQ0_tW_normal.jpeg","description":"The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the multidisciplinary cancer care team.","id_on_source":"ACCCBuzz","tweeter_id":"49718615","geo":{"lt":39.084,"ln":-77.15276,"country":"US"},"followers":2116},"tweet_id":"759052663149375488"},{"url":"http:\/\/twitter.com\/neuherman\/statuses\/759068800352477184","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-29T16:51:19+00:00","author":{"name":"N. Emil U. Hermansen","url":"https:\/\/www.researchgate.net\/profile\/Niels_Emil_Hermansen","image":"https:\/\/pbs.twimg.com\/profile_images\/816283350109392896\/xatq8EAj_normal.jpg","description":"MD, PhD. Senior resident in hematology. Board member of Danish Myeloma Study Group.","id_on_source":"neuherman","tweeter_id":"292516716","geo":{"lt":55.64152,"ln":12.08035,"country":"DK"},"followers":318},"tweet_id":"759068800352477184"},{"url":"http:\/\/twitter.com\/Taxkourel\/statuses\/759092665942208512","license":"gnip","rt":["MyelomaTeacher"],"citation_ids":[10065061],"posted_on":"2016-07-29T18:26:09+00:00","author":{"name":"Taxiarchis Kourelis","image":"https:\/\/pbs.twimg.com\/profile_images\/645004235591979008\/NCzeLuVE_normal.jpg","description":"The MADest DOG at Mayo Clinic (MAD=Myeloma,Amyloid, Dysproteinemia, DOG=Disease Oriented Group).Hate all things Congophilic.Tweets are my own.","id_on_source":"Taxkourel","tweeter_id":"3406182010","geo":{"lt":null,"ln":null},"followers":228},"tweet_id":"759092665942208512"},{"url":"http:\/\/twitter.com\/VJHemOnc\/statuses\/759096149944987652","license":"gnip","rt":["TheLancetOncol"],"citation_ids":[10065061],"posted_on":"2016-07-29T18:40:00+00:00","author":{"name":"VJHemOnc","url":"http:\/\/www.vjhemonc.com","image":"https:\/\/pbs.twimg.com\/profile_images\/725270166603464704\/v5CYY83F_normal.jpg","description":"Video Journal of Hematological Oncology is dedicated to providing trusted information, to improve knowledge, understanding and awareness of hematological cancer","id_on_source":"VJHemOnc","tweeter_id":"3187500729","geo":{"lt":null,"ln":null},"followers":2233},"tweet_id":"759096149944987652"},{"url":"http:\/\/twitter.com\/Dr_Chen_Wang\/statuses\/759264601414377472","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-30T05:49:22+00:00","author":{"name":"Chen Wang","url":"https:\/\/www.researchgate.net\/profile\/Chen_Wang97","image":"https:\/\/pbs.twimg.com\/profile_images\/711945531916820480\/8MhHWjii_normal.jpg","description":"Just a medical graduate, did some research on POEMS syndrome, and hope to become a hematologist in the near future","id_on_source":"Dr_Chen_Wang","tweeter_id":"711942951279026176","geo":{"lt":null,"ln":null},"followers":13},"tweet_id":"759264601414377472"},{"url":"http:\/\/twitter.com\/Mohty_EBMT\/statuses\/759408578591621120","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-30T15:21:28+00:00","author":{"name":"Mohamad Mohty","url":"http:\/\/www.ebmt.org","image":"https:\/\/pbs.twimg.com\/profile_images\/480924346299346944\/OOXDgK3a_normal.jpeg","description":"Professor of Hematology and president of the European society for Blood and Marrrow Transplantation (EBMT)","id_on_source":"Mohty_EBMT","tweeter_id":"2626263112","geo":{"lt":null,"ln":null},"followers":2766},"tweet_id":"759408578591621120"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/759422098653716480","license":"gnip","citation_ids":[10065061],"posted_on":"2016-07-30T16:15:12+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"759422098653716480"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/759425976250007552","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-07-30T16:30:36+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"759425976250007552"},{"url":"http:\/\/twitter.com\/VaroqueauxN\/statuses\/759503675140214785","license":"gnip","rt":["TheLancetOncol"],"citation_ids":[10065061],"posted_on":"2016-07-30T21:39:21+00:00","author":{"name":"VaroqueauxN","image":"https:\/\/pbs.twimg.com\/profile_images\/885589768733696000\/QnkCRHAq_normal.jpg","description":"ce tweet est personnel et n'engage que moi","id_on_source":"VaroqueauxN","tweeter_id":"701025807385423872","geo":{"lt":null,"ln":null},"followers":121},"tweet_id":"759503675140214785"},{"url":"http:\/\/twitter.com\/Mohty_EBMT\/statuses\/759784672675045376","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-31T16:15:56+00:00","author":{"name":"Mohamad Mohty","url":"http:\/\/www.ebmt.org","image":"https:\/\/pbs.twimg.com\/profile_images\/480924346299346944\/OOXDgK3a_normal.jpeg","description":"Professor of Hematology and president of the European society for Blood and Marrrow Transplantation (EBMT)","id_on_source":"Mohty_EBMT","tweeter_id":"2626263112","geo":{"lt":null,"ln":null},"followers":2766},"tweet_id":"759784672675045376"},{"url":"http:\/\/twitter.com\/CGiampalmi\/statuses\/759788647239462912","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-07-31T16:31:44+00:00","author":{"name":"Carole S Giampalmi","image":"https:\/\/pbs.twimg.com\/profile_images\/673310238087520256\/7cmWMq3g_normal.jpg","description":"SMM Mayo, Roch 5\/2005. 2 HPTh surgeries. Related? MM ptrnl grndmthr. Lt chains ratio sporadic (10 to 5). Trisomy 11. Cyclin D1. MDR1 gene. Healed BRONJ. SMM?","id_on_source":"CGiampalmi","tweeter_id":"2953567096","geo":{"lt":null,"ln":null},"followers":163},"tweet_id":"759788647239462912"},{"url":"http:\/\/twitter.com\/NextGEN_Ltd\/statuses\/759980720249049088","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-08-01T05:14:58+00:00","author":{"name":"\u0412\u043b\u0430\u0434","image":"https:\/\/pbs.twimg.com\/profile_images\/2342353963\/irjhyyc7ed67fugjx2fk_normal.jpeg","id_on_source":"NextGEN_Ltd","tweeter_id":"443359139","geo":{"lt":null,"ln":null},"followers":89},"tweet_id":"759980720249049088"},{"url":"http:\/\/twitter.com\/MayoCancerCare\/statuses\/760120401158483968","license":"gnip","citation_ids":[10065061],"posted_on":"2016-08-01T14:30:00+00:00","author":{"name":"Mayo Cancer Care","url":"http:\/\/www.mayoclinic.org\/cancer","image":"https:\/\/pbs.twimg.com\/profile_images\/461875284698857472\/9NdGrFuy_normal.jpeg","description":"Mayo Clinic Cancer Center combines personalized #cancertreatment with leading-edge #cancerresearch to provide unparalleled #cancer care.","id_on_source":"MayoCancerCare","tweeter_id":"2396756364","geo":{"lt":null,"ln":null},"followers":4442},"tweet_id":"760120401158483968"},{"url":"http:\/\/twitter.com\/AnaRRubio\/statuses\/760122809758674944","license":"gnip","citation_ids":[10065061],"posted_on":"2016-08-01T14:39:34+00:00","author":{"name":"Ana Rosa Rubio","image":"https:\/\/pbs.twimg.com\/profile_images\/468605431154487297\/wA8L5GlH_normal.jpeg","description":"Farmacia Hospitalaria. Board Certified Oncology Pharmacist","id_on_source":"AnaRRubio","tweeter_id":"2509238610","geo":{"lt":null,"ln":null},"followers":659},"tweet_id":"760122809758674944"},{"url":"http:\/\/twitter.com\/IMFmyeloma\/statuses\/760180425830506497","license":"gnip","rt":["MayoCancerCare"],"citation_ids":[10065061],"posted_on":"2016-08-01T18:28:31+00:00","author":{"name":"IMF - Myeloma.org","url":"http:\/\/www.myeloma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/851822555472302080\/b1jZjs6M_normal.jpg","description":"Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.","id_on_source":"IMFmyeloma","tweeter_id":"34340707","geo":{"lt":34.17223,"ln":-118.37897,"country":"US"},"followers":6684},"tweet_id":"760180425830506497"},{"url":"http:\/\/twitter.com\/MistyACallahan\/statuses\/760180564418637824","license":"gnip","rt":["MayoCancerCare"],"citation_ids":[10065061],"posted_on":"2016-08-01T18:29:04+00:00","author":{"name":"Misty Callahan","url":"http:\/\/www.mistycallahan.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/905976318055129089\/AOsSSDKE_normal.jpg","description":"Traffic Reporter. @CSLIChicago Fellow, history nerd, book nerd, multiple myeloma activist. Opinions are my own. RT's \u2260 endorsements","id_on_source":"MistyACallahan","tweeter_id":"167510425","geo":{"lt":41.85003,"ln":-87.65005,"country":"US"},"followers":3037},"tweet_id":"760180564418637824"},{"url":"http:\/\/twitter.com\/VincentRK\/statuses\/760185620266299392","license":"gnip","rt":["MayoCancerCare"],"citation_ids":[10065061],"posted_on":"2016-08-01T18:49:10+00:00","author":{"name":"Vincent Rajkumar","url":"http:\/\/bit.ly\/Z4PHPv","image":"https:\/\/pbs.twimg.com\/profile_images\/3418263560\/a40cbe1b5676b01dff5a8eb86e87c099_normal.jpeg","description":"Edward W & Betty Knight Scripps Professor, Mayo Clinic; Editor, Blood Cancer J; Assoc Editor, Mayo Clin Proceedings; No Financial COI http:\/\/tinyurl.com\/houbsqb","id_on_source":"VincentRK","tweeter_id":"24261916","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":5435},"tweet_id":"760185620266299392"},{"url":"http:\/\/twitter.com\/PublicHealthRTs\/statuses\/760185902048092162","license":"gnip","rt":["MayoCancerCare"],"citation_ids":[10065061],"posted_on":"2016-08-01T18:50:17+00:00","author":{"name":"I Love Public Health","url":"http:\/\/ilovepublichealthreposts.tumblr.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/596123466232942592\/e1Y0zhGH_normal.jpg","description":"Trying to use my social media powers for good. Promoting #PublicHealth knowledge\/trends\/news one (re)tweet at a time.","id_on_source":"PublicHealthRTs","tweeter_id":"2422072088","geo":{"lt":39.76,"ln":-98.5,"country":"US"},"followers":1477},"tweet_id":"760185902048092162"},{"url":"http:\/\/twitter.com\/ThiloZander\/statuses\/760196363950944256","license":"gnip","rt":["MayoCancerCare"],"citation_ids":[10065061],"posted_on":"2016-08-01T19:31:51+00:00","author":{"name":"Thilo J Zander, MD","url":"http:\/\/www.onkologie.ch","image":"https:\/\/pbs.twimg.com\/profile_images\/602826213195968512\/NxSTZovE_normal.jpg","description":"Medical Oncologist. Head of Lymphoma & Myeloma Service. Lucerne Cancer Center. Tweets and opinions are my own.","id_on_source":"ThiloZander","tweeter_id":"3155271593","geo":{"lt":47.16667,"ln":8.16667,"country":"CH"},"followers":359},"tweet_id":"760196363950944256"},{"url":"http:\/\/twitter.com\/afshanmalikmd\/statuses\/760249278514262017","license":"gnip","rt":["MayoCancerCare"],"citation_ids":[10065061],"posted_on":"2016-08-01T23:02:07+00:00","author":{"name":"Afshan Malik, MD","url":"http:\/\/www.afshanmalikmd.com","image":"https:\/\/pbs.twimg.com\/profile_images\/667761030806806528\/Qpoo3gvR_normal.jpg","description":"Hematology Oncology, NYC. @themyelomablog","id_on_source":"afshanmalikmd","tweeter_id":"52679352","geo":{"lt":43.00035,"ln":-75.4999,"country":"US"},"followers":219},"tweet_id":"760249278514262017"},{"url":"http:\/\/twitter.com\/SandyWong02111\/statuses\/760383370400587776","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-08-02T07:54:57+00:00","author":{"name":"Sandy Wong","url":"http:\/\/profiles.ucsf.edu\/sandy.w.wong","image":"https:\/\/pbs.twimg.com\/profile_images\/659796278239473664\/dXIxHTjs_normal.jpg","description":"UCSF Hematologist and BMT physician","id_on_source":"SandyWong02111","tweeter_id":"4050824739","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":110},"tweet_id":"760383370400587776"},{"url":"http:\/\/twitter.com\/Cecilia_Hemato\/statuses\/761264589149536256","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-08-04T18:16:36+00:00","author":{"name":"Cecilia","image":"https:\/\/pbs.twimg.com\/profile_images\/754557102992068610\/Seu6zdlM_normal.jpg","description":"Haematology consultant in beautiful Norway. \nHigh tendency to rant about many subjects, although you will see haematogy here!","id_on_source":"Cecilia_Hemato","tweeter_id":"405099036","geo":{"lt":62,"ln":10,"country":"NO"},"followers":305},"tweet_id":"761264589149536256"},{"url":"http:\/\/twitter.com\/Celgene_Myeloma\/statuses\/764197263421956096","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-08-12T20:30:00+00:00","author":{"name":"Celgene in Myeloma","image":"https:\/\/pbs.twimg.com\/profile_images\/903604738213781505\/CBgj84AG_normal.jpg","description":"Dedicated to providing education and resources for patients with multiple myeloma and their healthcare providers. Our guidelines: http:\/\/bit.ly\/2xK38VR","id_on_source":"Celgene_Myeloma","tweeter_id":"2164890637","geo":{"lt":40.74149,"ln":-74.35959,"country":"US"},"followers":2321},"tweet_id":"764197263421956096"},{"url":"http:\/\/twitter.com\/myeloma_samps\/statuses\/764204751110017025","license":"gnip","rt":["VincentRK"],"citation_ids":[10065061],"posted_on":"2016-08-12T20:59:45+00:00","author":{"name":"SAMPS MYELOMA","url":"http:\/\/www.southernalbertamyeloma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/726804627534946304\/fxYR4l4s_normal.jpg","description":"SAMPS is a Volunteer Organization Committed to providing Support to Warriors, Caregivers and their Families. Our vision is Hope for Improved Quality of life.","id_on_source":"myeloma_samps","tweeter_id":"724217522254270464","geo":{"lt":51.05011,"ln":-114.08529,"country":"CA"},"followers":24},"tweet_id":"764204751110017025"},{"url":"http:\/\/twitter.com\/Taxkourel\/statuses\/764636270756761604","license":"gnip","citation_ids":[10065061],"posted_on":"2016-08-14T01:34:27+00:00","author":{"name":"Taxiarchis Kourelis","image":"https:\/\/pbs.twimg.com\/profile_images\/645004235591979008\/NCzeLuVE_normal.jpg","description":"The MADest DOG at Mayo Clinic (MAD=Myeloma,Amyloid, Dysproteinemia, DOG=Disease Oriented Group).Hate all things Congophilic.Tweets are my own.","id_on_source":"Taxkourel","tweeter_id":"3406182010","geo":{"lt":null,"ln":null},"followers":228},"tweet_id":"764636270756761604"},{"url":"http:\/\/twitter.com\/szusmani\/statuses\/764821213290045440","license":"gnip","citation_ids":[10065061],"posted_on":"2016-08-14T13:49:21+00:00","author":{"name":"Saad Usmani","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000183096480\/a59c3a441593739eceb443f5e7bbfda7_normal.jpeg","description":"Chief, Plasma Cell Disorders; Director, Clinical Research in Hem Malignancies (Levine Cancer Institute). Clinician, researcher, cricket fan, views are my own","id_on_source":"szusmani","tweeter_id":"83911786","geo":{"lt":35.22709,"ln":-80.84313,"country":"US"},"followers":1961},"tweet_id":"764821213290045440"},{"url":"http:\/\/twitter.com\/Transplant_Doc\/statuses\/764899527371304960","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-08-14T19:00:33+00:00","author":{"name":"Muzaffar Qazilbash","url":"http:\/\/faculty.mdanderson.org\/Muzaffar_Qazilbash\/Default.asp","image":"https:\/\/pbs.twimg.com\/profile_images\/1805143659\/Profile_compressed_pic-_020412_normal.jpg","description":"Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own","id_on_source":"Transplant_Doc","tweeter_id":"162587280","geo":{"lt":null,"ln":null},"followers":3421},"tweet_id":"764899527371304960"},{"url":"http:\/\/twitter.com\/IMFmyeloma\/statuses\/764947001054068736","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-08-14T22:09:11+00:00","author":{"name":"IMF - Myeloma.org","url":"http:\/\/www.myeloma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/851822555472302080\/b1jZjs6M_normal.jpg","description":"Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.","id_on_source":"IMFmyeloma","tweeter_id":"34340707","geo":{"lt":34.17223,"ln":-118.37897,"country":"US"},"followers":6684},"tweet_id":"764947001054068736"},{"url":"http:\/\/twitter.com\/lascocancerfund\/statuses\/764954404734795776","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-08-14T22:38:36+00:00","author":{"name":"Robert D. Lasco","url":"http:\/\/lascocancerfund.org","image":"https:\/\/pbs.twimg.com\/profile_images\/782648175509196800\/D20JNFlY_normal.jpg","description":"Education and Awareness Exposing The Shadow's Of Multiple Myeloma.\r\nPublic Charity\/ Non-Profit\/ 5o1c3\nI'm a patient advocate","id_on_source":"lascocancerfund","tweeter_id":"33746469","geo":{"lt":35.22709,"ln":-80.84313,"country":"US"},"followers":220},"tweet_id":"764954404734795776"},{"url":"http:\/\/twitter.com\/Celgene_Myeloma\/statuses\/767828693372768257","license":"gnip","citation_ids":[10065061],"posted_on":"2016-08-22T21:00:00+00:00","author":{"name":"Celgene in Myeloma","image":"https:\/\/pbs.twimg.com\/profile_images\/903604738213781505\/CBgj84AG_normal.jpg","description":"Dedicated to providing education and resources for patients with multiple myeloma and their healthcare providers. Our guidelines: http:\/\/bit.ly\/2xK38VR","id_on_source":"Celgene_Myeloma","tweeter_id":"2164890637","geo":{"lt":40.74149,"ln":-74.35959,"country":"US"},"followers":2321},"tweet_id":"767828693372768257"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/791307251780820997","license":"gnip","citation_ids":[10065061],"posted_on":"2016-10-26T15:55:25+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"791307251780820997"},{"url":"http:\/\/twitter.com\/pmctrawler\/statuses\/793344327938215936","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-01T06:50:02+00:00","author":{"name":"PubMed Commons Trawl","url":"https:\/\/gist.github.com\/anonymous\/7167231","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000649264479\/999a1106baee29a2410d5f41eaa8040e_normal.jpeg","description":"Tweets when articles get their first Commons comment. Not a service of or sanctioned by NIH. Experimental; accuracy not guaranteed!","id_on_source":"pmctrawler","tweeter_id":"2156389052","geo":{"lt":null,"ln":null},"followers":192},"tweet_id":"793344327938215936"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/794169853208854528","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-03T13:30:22+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"794169853208854528"},{"url":"http:\/\/twitter.com\/VincentRK\/statuses\/794565192428318720","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-11-04T15:41:18+00:00","author":{"name":"Vincent Rajkumar","url":"http:\/\/bit.ly\/Z4PHPv","image":"https:\/\/pbs.twimg.com\/profile_images\/3418263560\/a40cbe1b5676b01dff5a8eb86e87c099_normal.jpeg","description":"Edward W & Betty Knight Scripps Professor, Mayo Clinic; Editor, Blood Cancer J; Assoc Editor, Mayo Clin Proceedings; No Financial COI http:\/\/tinyurl.com\/houbsqb","id_on_source":"VincentRK","tweeter_id":"24261916","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":5435},"tweet_id":"794565192428318720"},{"url":"http:\/\/twitter.com\/MayoMyeloma\/statuses\/795673440749584384","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-11-07T17:05:05+00:00","author":{"name":"Mayo Myeloma","url":"http:\/\/www.msmart.org","image":"https:\/\/pbs.twimg.com\/profile_images\/132886714\/Myeloma_normal.jpg","description":"Vincent Rajkumar, MD, Professor of Medicine, on behalf of the Mayo Clinic Myeloma Group","id_on_source":"MayoMyeloma","tweeter_id":"30386069","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":4795},"tweet_id":"795673440749584384"},{"url":"http:\/\/twitter.com\/agarwalonc\/statuses\/795798803257303040","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-08T01:23:14+00:00","author":{"name":"Amit Agarwal","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000396360956\/d2e9954729756f7dbc8dbc69b019b58b_normal.jpeg","description":"Assistant Professor of Medicine, University of Arizona. Clinical and Research Focus- Myeloma and Lymphoma.","id_on_source":"agarwalonc","tweeter_id":"20520873","geo":{"lt":null,"ln":null},"followers":272},"tweet_id":"795798803257303040"},{"url":"http:\/\/twitter.com\/IMFsupport\/statuses\/795957646100746240","license":"gnip","rt":["agarwalonc"],"citation_ids":[10065061],"posted_on":"2016-11-08T11:54:25+00:00","author":{"name":"Robin Tuohy","url":"http:\/\/myeloma.org","image":"https:\/\/pbs.twimg.com\/profile_images\/854063793558528000\/PByjypqr_normal.jpg","description":"Senior Director Support Groups, International Myeloma Foundation.   Husband, Michael, dx w\/ myeloma 2000. Living well thx to treatment, research & IMF.","id_on_source":"IMFsupport","tweeter_id":"987194570","geo":{"lt":41.50232,"ln":-72.97872,"country":"US"},"followers":1122},"tweet_id":"795957646100746240"},{"url":"http:\/\/twitter.com\/leshune\/statuses\/795965581442826242","license":"gnip","rt":["agarwalonc"],"citation_ids":[10065061],"posted_on":"2016-11-08T12:25:57+00:00","author":{"name":"Leyla Shune MD","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000740026071\/a0dfddd1cfc9538f69e42bd39ca64152_normal.png","description":"Bone marrow transplant physician","id_on_source":"leshune","tweeter_id":"420116171","geo":{"lt":null,"ln":null},"followers":152},"tweet_id":"795965581442826242"},{"url":"http:\/\/twitter.com\/Mohty_EBMT\/statuses\/795970133156106240","license":"gnip","rt":["agarwalonc"],"citation_ids":[10065061],"posted_on":"2016-11-08T12:44:02+00:00","author":{"name":"Mohamad Mohty","url":"http:\/\/www.ebmt.org","image":"https:\/\/pbs.twimg.com\/profile_images\/480924346299346944\/OOXDgK3a_normal.jpeg","description":"Professor of Hematology and president of the European society for Blood and Marrrow Transplantation (EBMT)","id_on_source":"Mohty_EBMT","tweeter_id":"2626263112","geo":{"lt":null,"ln":null},"followers":2766},"tweet_id":"795970133156106240"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/797128556174315520","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-11T17:27:12+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"797128556174315520"},{"url":"http:\/\/twitter.com\/dr_abdulaleem\/statuses\/797131314856128512","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-11-11T17:38:10+00:00","author":{"name":"Mohammed Abdul Aleem","image":"https:\/\/pbs.twimg.com\/profile_images\/828164989009674241\/NvnT3vV5_normal.jpg","description":"Pathology Senior Resident,\nOMC \ud83c\uddee\ud83c\uddf3\ninterest areas - #Pulmpath #InfectiousPathology\nArt lover, 24\/7 #Pathology and #Chess #foodie #innovativemind","id_on_source":"dr_abdulaleem","tweeter_id":"103507211","geo":{"lt":17.38405,"ln":78.45636,"country":"IN"},"followers":1584},"tweet_id":"797131314856128512"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/798269656767332352","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-14T21:01:31+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"798269656767332352"},{"url":"http:\/\/twitter.com\/queizan\/statuses\/798292881719103488","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-11-14T22:33:49+00:00","author":{"name":"Dr. Jos\u00e9 A. Queiz\u00e1n","image":"https:\/\/pbs.twimg.com\/profile_images\/805313113016799232\/jBSTAjA7_normal.jpg","description":"Medico Especialista en Hematologia y Hemoterapia","id_on_source":"queizan","tweeter_id":"2334315479","geo":{"lt":null,"ln":null},"followers":403},"tweet_id":"798292881719103488"},{"url":"http:\/\/twitter.com\/VincentRK\/statuses\/798537035476766722","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-11-15T14:44:00+00:00","author":{"name":"Vincent Rajkumar","url":"http:\/\/bit.ly\/Z4PHPv","image":"https:\/\/pbs.twimg.com\/profile_images\/3418263560\/a40cbe1b5676b01dff5a8eb86e87c099_normal.jpeg","description":"Edward W & Betty Knight Scripps Professor, Mayo Clinic; Editor, Blood Cancer J; Assoc Editor, Mayo Clin Proceedings; No Financial COI http:\/\/tinyurl.com\/houbsqb","id_on_source":"VincentRK","tweeter_id":"24261916","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":5435},"tweet_id":"798537035476766722"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/798537401908023296","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-15T14:45:27+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"798537401908023296"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/798885932720070656","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-16T13:50:23+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"798885932720070656"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/798994148175073280","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-16T21:00:24+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"798994148175073280"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/798996931469070336","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-16T21:11:27+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"798996931469070336"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/798997910704812032","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-16T21:15:21+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"798997910704812032"},{"url":"http:\/\/twitter.com\/BindingSiteHaem\/statuses\/799550690519646208","license":"gnip","citation_ids":[10065061],"posted_on":"2016-11-18T09:51:54+00:00","author":{"name":"Binding Site","url":"http:\/\/www.bindingsite.com","image":"https:\/\/pbs.twimg.com\/profile_images\/466145479625949187\/lZH6z1lj_normal.png","description":"Clinical utility of free light chains (Freelite) & heavy\/light chains (Hevylite) in monoclonal gammopathy #myeloma #nephrology Disclaimer http:\/\/hub.am\/1jLoIuK","id_on_source":"BindingSiteHaem","tweeter_id":"875434993","geo":{"lt":52.48142,"ln":-1.89983,"country":"GB"},"followers":827},"tweet_id":"799550690519646208"},{"url":"http:\/\/twitter.com\/elyarams\/statuses\/799579416456298497","license":"gnip","rt":["BindingSiteHaem"],"citation_ids":[10065061],"posted_on":"2016-11-18T11:46:03+00:00","author":{"name":"Elyara Soares","image":"https:\/\/pbs.twimg.com\/profile_images\/849310685599346690\/IBuFKSLi_normal.jpg","id_on_source":"elyarams","tweeter_id":"56198013","geo":{"lt":42.27756,"ln":-83.74088,"country":"US"},"followers":181},"tweet_id":"799579416456298497"},{"url":"http:\/\/twitter.com\/VincentRK\/statuses\/800430848533114880","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-11-20T20:09:20+00:00","author":{"name":"Vincent Rajkumar","url":"http:\/\/bit.ly\/Z4PHPv","image":"https:\/\/pbs.twimg.com\/profile_images\/3418263560\/a40cbe1b5676b01dff5a8eb86e87c099_normal.jpeg","description":"Edward W & Betty Knight Scripps Professor, Mayo Clinic; Editor, Blood Cancer J; Assoc Editor, Mayo Clin Proceedings; No Financial COI http:\/\/tinyurl.com\/houbsqb","id_on_source":"VincentRK","tweeter_id":"24261916","geo":{"lt":44.02163,"ln":-92.4699,"country":"US"},"followers":5435},"tweet_id":"800430848533114880"},{"url":"http:\/\/twitter.com\/DQBMD\/statuses\/800855630093369344","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-11-22T00:17:16+00:00","author":{"name":"Qaiser Bashir","image":"https:\/\/pbs.twimg.com\/profile_images\/720985321224077312\/IhoOD56t_normal.jpg","description":"Stem Cell Transplantation | Myeloma | Leukemia | Clinical Trials | Personal views","id_on_source":"DQBMD","tweeter_id":"293100589","geo":{"lt":29.76328,"ln":-95.36327,"country":"US"},"followers":248},"tweet_id":"800855630093369344"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/804755971541078016","license":"gnip","citation_ids":[10065061],"posted_on":"2016-12-02T18:35:49+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"804755971541078016"},{"url":"http:\/\/twitter.com\/AdaptiveBiotech\/statuses\/805500106317430784","license":"gnip","citation_ids":[10065061],"posted_on":"2016-12-04T19:52:45+00:00","author":{"name":"Adaptive Biotech","url":"http:\/\/www.adaptivebiotech.com","image":"https:\/\/pbs.twimg.com\/profile_images\/604165819178696704\/q9LoxXxI_normal.png","description":"Adaptive is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.","id_on_source":"AdaptiveBiotech","tweeter_id":"543650254","geo":{"lt":47.60621,"ln":-122.33207,"country":"US"},"followers":1884},"tweet_id":"805500106317430784"},{"url":"http:\/\/twitter.com\/Sorena997\/statuses\/805500356985655296","license":"gnip","rt":["AdaptiveBiotech"],"citation_ids":[10065061],"posted_on":"2016-12-04T19:53:45+00:00","author":{"name":"Sorena","url":"http:\/\/www.cityofhope.org","image":"https:\/\/pbs.twimg.com\/profile_images\/820316132292726785\/r0ekzvEG_normal.jpg","description":"Chief-Informatics-Officer @cityofhope: Cancer & Diabetes Research\/Digital Health\/IT\/ *Informatics*\/OMICS\/Interoperability\/DataScience\/ PrecisionMedicine\/@ci4cc","id_on_source":"Sorena997","tweeter_id":"16195981","geo":{"lt":34.14778,"ln":-118.14452,"country":"US"},"followers":1645},"tweet_id":"805500356985655296"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/806129853368045568","license":"gnip","citation_ids":[10065061],"posted_on":"2016-12-06T13:35:08+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"806129853368045568"},{"url":"http:\/\/twitter.com\/razan_mohty\/statuses\/806157791870132224","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2016-12-06T15:26:09+00:00","author":{"name":"razan mohty","image":"https:\/\/pbs.twimg.com\/profile_images\/839866694168428545\/2t4R1CrA_normal.jpg","id_on_source":"razan_mohty","tweeter_id":"244909815","geo":{"lt":null,"ln":null},"followers":41},"tweet_id":"806157791870132224"},{"url":"http:\/\/twitter.com\/sarah_0875\/statuses\/807478104889458688","license":"gnip","rt":["szusmani"],"citation_ids":[10065061],"posted_on":"2016-12-10T06:52:37+00:00","author":{"name":"\ud83d\udc95Sarah Henshaw \ud83d\udc95","image":"https:\/\/pbs.twimg.com\/profile_images\/802646859248521216\/9hIG8bGa_normal.jpg","description":"Myeloma Clinical Nurse Specialist at Nottingham University Hospitals (my views are my own!) and Notts County season ticket holder!! COYP!!! \u25fc\ufe0f\u25fb\ufe0f\u25fc\ufe0f\u25fb\ufe0f\u25fc\ufe0f\u25fb\ufe0f\u25fc\ufe0f","id_on_source":"sarah_0875","tweeter_id":"24183682","geo":{"lt":null,"ln":null},"followers":169},"tweet_id":"807478104889458688"},{"url":"http:\/\/twitter.com\/elizabeth_dorcy\/statuses\/858053880315359232","license":"gnip","citation_ids":[10065061],"posted_on":"2017-04-28T20:22:41+00:00","author":{"name":"elizabeth d'orcy","image":"https:\/\/pbs.twimg.com\/profile_images\/876084144484306948\/XpJPmySG_normal.jpg","description":"Hemepath| Patchwork| Black olives","id_on_source":"elizabeth_dorcy","tweeter_id":"231902685","geo":{"lt":null,"ln":null},"followers":487},"tweet_id":"858053880315359232"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/859160545827663872","license":"gnip","citation_ids":[10065061],"posted_on":"2017-05-01T21:40:11+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15396},"tweet_id":"859160545827663872"},{"url":"http:\/\/twitter.com\/rodrigonunescal\/statuses\/859161173509500929","license":"gnip","rt":["mtmdphd"],"citation_ids":[10065061],"posted_on":"2017-05-01T21:42:40+00:00","author":{"name":"Rodrigo Nunes Cal","url":"https:\/\/br.linkedin.com\/in\/rodrigo-nunes-cal-351706144","image":"https:\/\/pbs.twimg.com\/profile_images\/897276870277943296\/BLZChTDp_normal.jpg","description":"Graduated in Biomedicine, master\u00b4s degree. Inspector of students since 2012. rodrigonunescal@yahoo.com Instagram: @rodrigonunescal1","id_on_source":"rodrigonunescal","tweeter_id":"716577519785394176","geo":{"lt":-20.81972,"ln":-49.37944,"country":"BR"},"followers":9601},"tweet_id":"859161173509500929"}],"facebook":[{"title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1076736022409338&id=909065465843062","license":"public","citation_ids":[10065061],"posted_on":"2016-07-27T17:12:11+00:00","summary":"Miyelomada minimal kal\u0131nt\u0131 hastal\u0131k temelli yeni yan\u0131t kriterlerini i\u00e7eren (sonunda bas\u0131l\u0131 halde) ve yan\u0131t de\u011ferlendirmede ak\u0131lda soru i\u015fareti b\u0131rakmayan g\u00fcncel bir IMWG derlemesi. Shaji ve b\u00fct\u00fcn di\u011fer miyeloma uzmanlar\u0131na bu geni\u015f, a\u00e7\u0131k ve iyi kaleme al\u0131n","author":{"name":"Hematoloji \u00dcniversitesi","url":"https:\/\/www.facebook.com\/909065465843062","facebook_wall_name":"Hematoloji \u00dcniversitesi","image":"https:\/\/graph.facebook.com\/909065465843062\/picture","id_on_source":"909065465843062"}},{"title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1754837394784100&id=1673989042868936","license":"public","citation_ids":[10065061],"posted_on":"2016-07-29T15:47:26+00:00","summary":"Newly published @imfmyeloma IMWG consensus criteria for response & MRD assessment in #myeloma #mmsm http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045%2816%2930206-6\/fulltext?rss=yes#.V5t55czEH5o.twitter","author":{"name":"Myeloma Teacher 's Multiple Myeloma Resource Page","url":"https:\/\/www.facebook.com\/1673989042868936","facebook_wall_name":"MyelomaTeacher 's Multiple Myeloma Resource Page","image":"https:\/\/graph.facebook.com\/1673989042868936\/picture","id_on_source":"1673989042868936"}}],"peer_reviews":[{"url":"https:\/\/pubpeer.com\/publications\/214318E0E1DFB3FC9A4BB28B0D0545#fb109301","license":"public","citation_ids":[10065061],"posted_on":"2016-11-01T14:37:33+00:00","summary":"Daniela Drandi | Oct 31 2016 17:31 ESTDr. Kumar S. and Colleagues gave a comprehensive description of the role of the ancestors (MFC and ASOqPCR) and the new high-throughput (NGF and NGS) MRD techniques in MM...","author":{"id_on_source":"Comment from PubMed Commons"},"pr_id":"pubpeer","publons_quality_score":null,"publons_significance_score":null,"publons_review_type":null,"publons_weighted_average":null,"publons_article_url":null,"pubpeer_publication_url":"https:\/\/pubpeer.com\/publications\/214318E0E1DFB3FC9A4BB28B0D0545"}]}}